Luhua (Michael) Wang, M.D.

Peer-Reviewed Articles

1. Wang L, Tang G, Medeiros JL, Xu J, Huang W, Yin CC, Wang M, Jain P, Lin P, Li S. MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma. Haematologica 106(5):1381-1389, 2021. e-Pub 2021. PMID: 32273477.
2. Strati P, Jain P, Johnson RJ, Forbes S, Feng L, Samaniego F, Rodriguez MA, Fayad LE, Hagemeister F, Westin J, Wang M, Neelapu SS, Nastoupil LJ, Fowler NH. Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma. Blood 137(8):1124-1129, 2021. e-Pub 2020. PMID: 32932518.
3. Dreyling M, Tam CS, Wang M , Smith SD, Ladetto M, Huang H, Novotny W, Co M, Romano A, Holmgren E, Huang J, Gouill SL. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. Future Oncol 17(3):255-262, 2021. e-Pub 2020. PMID: 32985902.
4. Jain P, Nastoupil L, Westin J, Lee HJ, Navsaria L, Steiner RE, Ahmed S, Moghrabi O, Oriabure O, Chen W, Badillo M, Flowers CR, Wang ML. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Br J Haematol 192(2):e38-e42, 2021. e-Pub 2020. PMID: 33152104.
5. Manasanch EE, Jain P, Chen W, Oriabure O, Badillo M, Feng L, Berkova Z, Orlowski RZ, Wang M. Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma. Am J Hematol 95(9):E232-E235, 2020. e-Pub 2020. PMID: 32390148.
6. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839-852, 2020. e-Pub 2020. PMID: 32888407.
7. Badillo M, Nava D, Rosa M, Chen W, Guerrero M, Wang M. Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma. Clin J Oncol Nurs 24(4):392-398, 2020. PMID: 32678359.
8. Strati P, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, Singh P, Mistry HE, Horowitz S, George S, Feng L, Kebriaei P, Shpall EJ, Neelapu SS, Tummala S, Chi TL. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4(16):3943-3951, 2020. PMID: 32822484.
9. Guo WH, Qi X, Yu X, Liu Y, Chung CI, Bai F, Lin X, Lu D, Wang L, Chen J, Su LH, Nomie KJ, Li F, Wang MC, Shu X, Onuchic JN, Woyach JA, Wang ML, Wang J. Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry. Nat Commun 11(1):4268, 2020. e-Pub 2020. PMID: 32848159.
10. Strati P, Ahmed MA, Fowler NH, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica 105(7):1907-1913, 2020. e-Pub 2019. PMID: 31601688.
11. Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad L, Lee HJ, Nair R, Steiner RE, Iyer SP, Rodriguez MA, Wang M, Flowers C, Neelapu SS, Nastoupil LJ. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv 4(13):2871-2883, 2020. PMID: 32589728.
12. Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leuk Lymphoma 61(6):1-8, 2020. e-Pub 2020. PMID: 31971032.
13. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623-629, 2020. e-Pub 2020. PMID: 32239765.
14. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 382(14):1331-1342, 2020. PMID: 32242358.
15. Lee HJ, Schmelz JL, Cramer F, Romaguera JE, Badillo M, Wang M. A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma. Br J Haematol 188(6):e94-e98, 2020. e-Pub 2020. PMID: 32057090.
16. Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv 4(6):1038-1050, 2020. PMID: 32191807.
17. Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma 61(2):1-9, 2020. e-Pub 2019. PMID: 31533521.
18. Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica 105(1):e26-e28, 2020. e-Pub 2019. PMID: 31073068.
19. Zhu F, Guo H, Bates PD, Zhang S, Zhang H, Nomie KJ, Li Y, Lu L, Seibold KR, Wang F, Rumball I, Cameron H, Hoang NM, Yang DT, Xu W, Zhang L, Wang M, Capitini CM, Rui L. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells. Leukemia 33(12):2898-2911, 2019. e-Pub 2019. PMID: 31123343.
20. Lee HC, Shah JJ, Feng L, Morphey A, Johnson RJ, Wesson ET, Wang ML, Alexanian R, Thomas SK, Orlowski RZ, Weber DM. A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Am J Hematol 94(12):E319-E322, 2019. e-Pub 2019. PMID: 31489991.
21. Fu S, Wang M, Zhao H, Li R, Lairson DR, Giordano SH, Zhao B, Du XL. Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma. Clin Lymphoma Myeloma Leuk 19(11):e616-e623, 2019. e-Pub 2019. PMID: 31563564.
22. Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Jain P, Frigault MM, Izumi R, Nguyen D, Patel P, Yin M, Dlugosz-Danecka M. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia 33(11):2762-2766, 2019. e-Pub 2019. PMID: 31558766.
23. Wang Y, Yang F, Wang ML. Immune Thrombocytopenia-A Neglected Adverse Event of PD-1 and PD-L1 Inhibitors in Clinical Trials-In Reply. JAMA Oncol 5(11):1641-1642, 2019. e-Pub 2019. PMID: 31536125.
24. Wang J, Wang J, Lopez E, Guo H, Zhang H, Liu Y, Chen Z, Huang S, Zhou S, Leeming A, Zhang RJ, Jung D, Shi H, Grundman H, Doakes D, Cui K, Jiang C, Ahmed M, Nomie K, Fang B, Wang M, Yao Y, Zhang L. Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma. Blood Cancer J 9(12):95, 2019. e-Pub 2019. PMID: 31780660.
25. Lee HC, Shah JJ, Feng L, Manasanch EE, Lu R, Morphey A, Crumpton B, Patel KK, Wang ML, Alexanian R, Thomas SK, Weber DM, Orlowski RZ. A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Blood Cancer J 9(10):80, 2019. e-Pub 2019. PMID: 31575851.
26. Saksena A, Yin CC, Xu J, Li J, Zhou J, Wang SA, Lin P, Tang G, Wang L, Wang M, Miranda RN, Medeiros LJ, Li S. CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form and a better prognosis. Hum Pathol 89:71-80, 2019. e-Pub 2019. PMID: 31054894.
27. Ning MS, Pinnix CC, Chapman BV, Gunther JR, Milgrom SA, Khoury JD, Jain P, Chen WY, Oriabure ON, Badillo MR, Wang LM, Dabaja BS. Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma. Blood Adv 3(13):2035-2039, 2019. PMID: 31289030.
28. Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma. Am J Hematol 94(6):E150-E153, 2019. e-Pub 2019. PMID: 30785215.
29. Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol 185(5):874-882, 2019. e-Pub 2019. PMID: 30919940.
30. Salles G, Gopal AK, Minnema MC, Wakamiya K, Feng H, Schecter JM, Wang M. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. Clin Lymphoma Myeloma Leuk 19(5):275-284, 2019. e-Pub 2019. PMID: 30795996.
31. Xu J, Wang L, Li J, Saksena A, Wang SA, Shen J, Hu Z, Lin P, Tang G, Yin CC, Wang M, Medeiros LJ, Li S. SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients. Am J Surg Pathol 43(5):710-716, 2019. e-Pub 2019. PMID: 30768440.
32. Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, Hernández-Rivas JÁ, Qi K, Deshpande S, Parisi L, Wang M. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow-up from a pooled analysis. Haematologica 104(5):e211-e214, 2019. e-Pub 2018. PMID: 30442728.
33. Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, Bell T, Zhang H, Han G, Lorence E, Badillo M, Zhou S, Sun Y, Di Francesco ME, Feng N, Haun R, Lan R, Mackintosh SG, Mao X, Song X, Zhang J, Pham LV, Lorenzi PL, Marszalek J, Heffernan T, Draetta G, Jones P, Futreal A, Nomie K, Wang L, Wang M. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med 11(491), 2019. PMID: 31068440.
34. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Yehia Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 41(5):1546, 2019. e-Pub 2019. PMID: 30990235.
35. Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Adv 3(9):1356-1367, 2019. PMID: 31036721.
36. Miao Y, Lin P, Saksena A, Xu J, Wang M, Romaguera J, Yin CC, Medeiros LJ, Li S. CD5-negative Mantle Cell Lymphoma: Clinicopathologic Correlations and Outcome in 58 Patients. Am J Surg Pathol 43(8):1052-1060. e-Pub 2019. PMID: 31045891.
37. Lee HJ, Badillo M, Romaguera J, Wang M. A phase II study of carfilzomib in the treatment of relapsed/refractory mantle cell lymphoma. Br J Haematol 184(3):460-462, 2019. e-Pub 2018. PMID: 29527676.
38. Li CJ, Jiang C, Liu Y, Bell T, Ma W, Ye Y, Huang S, Guo H, Zhang H, Wang L, Wang J, Nomie K, Zhang L, Wang M. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. Mol Cancer Ther 18(2):267-277, 2019. e-Pub 2018. PMID: 30413649.
39. Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang ML, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. J Clin Oncol 37(6):471-480, 2019. e-Pub 2019. PMID: 30615550.
40. Fu S, Wang M, Li R, Lairson DR, Zhao B, Du XL. Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995-2013: Findings from Texas and national SEER areas. Cancer Epidemiol 58:89-97, 2019. e-Pub 2018. PMID: 30528835.
41. Jain P, Kanagal-Shamanna R, San Lucas FA, Nastoupil L, Romaguera J, Fayad L, Oki Y, Westin JR, Medeiros LJ, Wang M, Fowler N. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. Br J Haematol 182(5):718-723, 2018. e-Pub 2017. PMID: 28771675.
42. Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, Pogue E, Ding Z, Lam L, Westin J, Davis RE, Young KH, Medeiros LJ, Ford RJ, Nomie K, Zhang L, Wang M. Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. Clin Cancer Res 24(16):3967-3980, 2018. e-Pub 2018. PMID: 29666304.
43. Dimopoulos M, Wang M, Maisnar V, Minarik J, Bensinger W, Mateos MV, Obreja M, Blaedel J, Moreau P. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol 11(1):49, 2018. e-Pub 2018. PMID: 29615082.
44. Huang S, Jiang C, Zhang H, Bell T, Guo H, Liu Y, Yao Y, Zeng D, Ahmed M, Nomie K, Zhang L, Wang M. The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma. Blood Cancer J 8(3):33, 2018. e-Pub 2018. PMID: 29559616.
45. Hu Z, Sun Y, Schlette EJ, Tang G, Li S, Xu J, Yin CC, Young KH, Patel KP, Miranda RN, Goswami M, Wang M, Jorgensen JL, Medeiros LJ, Wang SA. CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. Mod Pathol 31(2):327-336, 2018. e-Pub 2017. PMID: 28984300.
46. Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 391(10121):659-667, 2018. e-Pub 2017. PMID: 29241979.
47. Xu J, Medeiros LJ, Saksena A, Wang M, Zhou J, Li J, Yin CC, Tang G, Wang L, Lin P, Li S. CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases. Oncotarget 9(14):11441-11450, 2018. e-Pub 2017. PMID: 29545910.
48. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One 13(3):e0191461, 2018. e-Pub 2018. PMID: 29538376.
49. Fu S, Wang M, Lairson DR, Li R, Zhao B, Du XL. Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas. Oncotarget 8(68):112516-112529, 2017. e-Pub 2017. PMID: 29348844.
50. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol 179(3):503-506, 2017. e-Pub 2016. PMID: 27378601.
51. Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, Cavazos N, Liu B, Yang S, Clow F, Goldberg JD, Beaupre D, Vermeulen J, Wildgust M, Wang M. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol 179(3):430-438, 2017. e-Pub 2017. PMID: 28832957.
52. Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, Hamadani M, Ghosh N, Reeder CB, Barnett E, Bravo MC, Martin P. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol 10(1):171, 2017. e-Pub 2017. PMID: 29096668.
53. Li Y, Wang F, Lu L, Zhu F, Huang S, Nomie K, Zhang L, Yang DT, Huang W, Kahl BS, Safe S, Wang M, Rui L. NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells. Blood Cancer J 7(12):632, 2017. e-Pub 2017. PMID: 29167454.
54. Liu Y, Yin Y, Zhang Z, Li CJ, Zhang H, Zhang D, Jiang C, Nomie K, Zhang L, Wang M, Zhao G. Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity. Eur J Med Chem 138:543-551, 2017. e-Pub 2017. PMID: 28704757.
55. Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, Segal J, Li S, Zhou S, Santos D, Richard S, Sharma S, Chen W, Oriabure O, Liu Y, Huang S, Guo H, Chen Z, Tao W, Li C, Wang J, Fang B, Wang J, Li L, Badillo M, Ahmed M, Thirumurthi S, Huang SY, Shao Y, Lam L, Yi Q, Wang YL, Wang M. B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy. Clin Cancer Res 23(15):4212-4223, 2017. e-Pub 2017. PMID: 28348046.
56. Jain P, Milgrom SA, Patel KP, Nastoupil L, Fayad L, Wang M, Pinnix CC, Dabaja BS, Smith GL, Yu J, Hu S, Bueso Ramos CE, Kanagal-Shamanna R, Medeiros LJ, Oki Y, Fowler N. Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. Br J Haematol 178(3):403-412, 2017. e-Pub 2017. PMID: 28382648.
57. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang M, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood 130(4):472-477, 2017. e-Pub 2017. PMID: 28522441.
58. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 39(6):1095-1100, 2017. e-Pub 2017. PMID: 28370694.
59. Kuruvilla J, Savona M, Baz R, Mau-Sorensen PM, Gabrail N, Garzon R, Stone R, Wang M, Savoie L, Martin P, Flinn I, Jacoby M, Unger TJ, Saint-Martin JR, Rashal T, Friedlander S, Carlson R, Kauffman M, Shacham S, Gutierrez M. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood 129(24):3175-3183, 2017. e-Pub 2017. PMID: 28468797.
60. Sun B, Fiskus W, Qian Y, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Saenz DT, Mill CP, Nowak AJ, Jain N, Zhang L, Wang M, Khoury JD, Coarfa C, Crews CM, Bhalla KN. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia 32(2):343-352. e-Pub 2017. PMID: 28663582.
61. Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist 22(5):549-553, 2017. e-Pub 2017. PMID: 28408615.
62. Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol 177(2):263-270, 2017. e-Pub 2017. PMID: 28340281.
63. Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, Zhang L, Fu K, Bi C, Li J, Jiang H, Meads MB, Jacobson T, Silva M, Distler A, Darville L, Zhang L, Han Y, Rebatchouk D, Di Liberto M, Moscinski LC, Koomen JM, Dalton WS, Shain KH, Wang M, Sotomayor E, Tao J. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun 8:14920, 2017. e-Pub 2017. PMID: 28416797.
64. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol 176(5):750-758, 2017. e-Pub 2016. PMID: 27983760.
65. Lee HJ, Chihara D, Wang M, Mouhayar E, Kim P. Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma. Leuk Lymphoma 57(12):1-3, 2016. e-Pub 2016. PMID: 27087288.
66. Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, Han van Krieken J, Medeiros LJ, Li Y, van Spriel AB, Young KH. Assessment of CD37 B-cell antigen and cell-of-origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood 128(26):3083-3100, 2016. e-Pub 2016. PMID: 27760757.
67. Mohanty A, Sandoval N, Das M, Pillai R, Chen L, Chen RW, Amin HM, Wang M, Marcucci G, Weisenburger DD, Rosen ST, Pham LV, Ngo VN. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma. Oncotarget 7(45):73558-73572, 2016. e-Pub 2016. PMID: 27713153.
68. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer 122(20):3145-3151, 2016. e-Pub 2016. PMID: 27351173.
69. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol 175(2):290-299, 2016. e-Pub 2016. PMID: 27448187.
70. Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špicka I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression free survival of high-risk patients in multiple myeloma. Blood 128(9):1174-80, 2016. e-Pub 2016. PMID: 27439911.
71. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Annals Oncol 27(7):1317-1323, 2016. e-Pub 2016. PMID: 27091808.
72. Lee SJ, Levitsky K, Parlati F, Bennett MK, Arastu-Kapur S, Kellerman L, Woo TF, Wong AF, Papadopoulos KP, Niesvizky R, Badros AZ, Vij R, Jagannath S, Siegel D, Wang M, Ahmann GJ, Kirk CJ. Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay. Br J Haematol 173(6):884-95, 2016. e-Pub 2016. PMID: 27071340.
73. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, Sarbassov dos D, Lorenzi PL, Huang X, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff M. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal 9(415):ra17, 2016. e-Pub 2016. PMID: 26884599.
74. Shah JJ, Feng L, Thomas SK, Berkova Z, Weber DM, Wang M, Qazilbash MH, Champlin RE, Mendoza TR, Cleeland C, Orlowski RZ. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J 6(2):e396, 2016. e-Pub 2016. PMID: 26871714.
75. Wang M, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, DeLa Rosa M, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 17(1):48-56, 2016. e-Pub 2015. PMID: 26640039.
76. Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang M, Romaguera JE. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol 172(1):80-8, 2016. e-Pub 2015. PMID: 26648336.
77. Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 16(1):36-42, 2016. e-Pub 2015. PMID: 26702475.
78. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 171(4):509-16, 2015. e-Pub 2015. PMID: 26260306.
79. Zhang L, Bi E, Hong S, Qian J, Zheng C, Wang M, Yi Q. CD4+ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma. Oncotarget 6(34):36032-40, 2015. e-Pub 2015. PMID: 26447613.
80. Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, Li L, Devaraj SG, Sharma S, Zhang L, Wang M, Saenz DT, Krieger S, Bradner JE, Bhalla KN. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood 126(13):1565-74, 2015. e-Pub 2015. PMID: 26254443.
81. Wang M, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results. Blood 126(6):739-45, 2015. e-Pub 2015. PMID: 26059948.
82. Furtado M, Wang M, Munneke B, McGreivy J, Beaupre DM, Rule S. Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma. Br J Haematol 170(1):131-4, 2015. e-Pub 2015. PMID: 25559624.
83. Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol 171(4):463-470. e-Pub 2015. PMID: 26213141.
84. Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, Champlin RE, Wang ML. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol 26(6):1175-9, 2015. e-Pub 2015. PMID: 25712454.
85. Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang XD, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZ. Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström's Macroglobulinemia. Clin Cancer Res 21(11):2538-45, 2015. e-Pub 2015. PMID: 25748087.
86. Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, Rodriguez MA, Fayad L, Neelapu SS, Samaniego F. Targeting Wnt pathway in mantle cell lymphoma-initiating cells. J Hematol Oncol 8:63, 2015. e-Pub 2015. PMID: 26048374.
87. Kongtim P, Qazilbash MH, Shah JJ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin R, Manasanch EE, Weber D, Orlowski RZ, Parmar S. High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. Bone Marrow Transplant 50(5):668-72, 2015. e-Pub 2015. PMID: 25730192.
88. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated liposomal doxorubicin replacing conventional doxorubicin in Standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk 15(3):152-8, 2015. e-Pub 2014. PMID: 25445468.
89. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang M, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA. Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor. J Clin Oncol 33(6):540-9, 2015. e-Pub 2014. PMID: 25154820.
90. Hao C, Wang L, Peng S, Cao M, Li H, Hu J, Huang X, Liu W, Zhang H, Wu S, Pataer A, Heymach JV, Eterovic AK, Zhang Q, Shaw KR, Chen K, Futreal A, Wang M, Hofstetter W, Mehran R, Rice D, Roth JA, Sepesi B, Swisher SG, Vaporciyan A, Walsh GL, Johnson FM, Fang B. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett 357(1):179-85, 2015. e-Pub 2014. PMID: 25444907.
91. Pham LV, Vang MT, Tamayo AT, Lu G, Challagundla P, Jorgensen JL, Rollo AA, Ou Z, Zhang L, Wang M, Ford RJ. Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease. Leuk Lymphoma 56(1):186-93, 2015. e-Pub 2014. PMID: 24611650.
92. Huang X, Cao M, Wang L, Wu S, Liu X, Li H, Zhang H, Wang RY, Sun X, Wei C, Baggerly KA, Roth JA, Wang M, Swisher SG, Fang B. Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380. Oncotarget 6(1):345-54, 2015. e-Pub 2014. PMID: 25514600.
93. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špicka I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A, ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372(2):142-52, 2015. e-Pub 2014. PMID: 25482145.
94. Vij R, Wang M, Jagannath S, Niesvizky R, Jakubowiak AJ, Kavalerchik E, Huang M, Siegel DS. Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. Leuk Lymphoma 56(10):2959-61, 2015. e-Pub 2015. PMID: 25699653.
95. Haque W, Voong KR, Shihadeh F, Arzu I, Pinnix C, Mazloom A, Medeiros LJ, Romaguera J, Rodriguez A, Wang M, Allen P, Dabaja B. Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients. Clin Lymphoma Myeloma Leuk 14(6):474-9, 2014. e-Pub 2014. PMID: 25108680.
96. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15(12):1311-8, 2014. e-Pub 2014. PMID: 25439689.
97. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 2014. e-Pub 2014. PMID: 24943107.
98. Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, Ou Z, Zhang L, Heymach JV, Gold KA, Minna J, Roth JA, Hofstetter WL, Swisher SG, Fang B. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst 106(9), 2014. e-Pub 2014. PMID: 25214559.
99. Cai Q, Chen Y, Zou D, Zhang L, Badillo M, Zhou S, Lopez E, Jiang W, Huang H, Lin T, Romaguera J, Wang M. Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma. Oncotarget 5(17):7368-80, 2014. PMID: 25228589.
100. Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood 124(7):1038-46, 2014. e-Pub 2014. PMID: 24920586.
101. Parmar S, Kongtim P, Champlin R, Dinh Y, Elgharably Y, Wang M, Bashir Q, Shah JJ, Shah N, Popat U, Giralt SA, Orlowski RZ, Qazilbash MH. Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant 49(8):1036-41, 2014. e-Pub 2014. PMID: 24887378.
102. Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H, Wang M, Qazilbash MH, Baladandayuthapani V, Berry D, Orlowski RZ, Lee MH, Yeung SC. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer 111(3):628-36, 2014. e-Pub 2014. PMID: 24921909.
103. Wang M, Popplewell LL, Collins RH, Winter JN, Goy A, Kaminski MS, Bartlett NL, Johnston PB, Lister J, Fanning SR, Tuscano JM, Beck JT, Kaya H, Robeva A, Fan J, Klimovsky J, Cheung W, Cherfi A, O'Connor OA. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol 165(4):510-8, 2014. e-Pub 2014. PMID: 24579926.
104. Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol 7(1):41, 2014. e-Pub 2014. PMID: 24886772.
105. Alexanian R, Wang M, Delasalle K, Wang S, Qazilbash M, Handy B, Weber D. Value of novel agents and intensive therapy for patients with multiple myeloma. Bone Marrow Transplant 49(3):422-5, 2014. e-Pub 2013. PMID: 24317125.
106. Axelrod M, Ou Z, Brett LK, Zhang L, Lopez ER, Tamayo AT, Gordon V, Ford RJ, Williams ME, Pham LV, Weber MJ, Wang ML. Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma. Leukemia 28(2):407-10, 2014. e-Pub 2013. PMID: 23979520.
107. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 28(2):373-83, 2014. e-Pub 2013. PMID: 23760401.
108. Chen Z, Orlowski RZ, Wang M, Kwak L, McCarty N. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood 123(14):2204-2208. e-Pub 2014. PMID: 24425802.
109. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 2013. e-Pub 2013. PMID: 24117234.
110. Zhang L, Pham LV, Newberry KJ, Ou Z, Liang R, Qian J, Sun L, Blonska M, You Y, Yang J, Lin X, Rollo A, Tamayo AT, Lee J, Ford RJ, Zhao X, Kwak LW, Yi Q, Wang M. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol Cancer Ther 12(11):2494-504, 2013. e-Pub 2013. PMID: 23990113.
111. Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 122(18):3122-8, 2013. e-Pub 2013. PMID: 24014245.
112. Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: Relevance of p53 and its clinical implications. Exp Hematol 41(8):719-30, 2013. e-Pub 2013. PMID: 23648290.
113. Wang M, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507-16, 2013. e-Pub 2013. PMID: 23782157.
114. Li Y, Gordon MW, Xu-Monette ZY, Visco C, Tzankov A, Zou D, Qiu L, Montes-Moreno S, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Ai W, Ponzoni M, Ferreri AJ, Winter JN, Go RS, Piris MA, Møller MB, Wu L, Wang M, Ramos KS, Medeiros LJ, Young KH. Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood 121(22):4529-40, 2013. e-Pub 2013. PMID: 23515929.
115. Alexanian R, Delasalle K, Wang M. High frequencies of response after limited primary therapy for multiple myeloma. Clin Lymphoma Myeloma Leuk 13(2):119-22, 2013. e-Pub 2012. PMID: 23260599.
116. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. Leukemia 227(9):1902-9. e-Pub 2013. PMID: 23545991.
117. Niesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res 19(8):2248-56, 2013. e-Pub 2013. PMID: 23447001.
118. Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, Zhang L, Ou Z, Li C, Sun L, Ford RJ, Pham LV. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol 41(1):67-78, 2013. e-Pub 2012. PMID: 22986101.
119. Chen Z, Pittman EF, Romaguera J, Fayad L, Wang M, Neelapu SS, McLaughlin P, Kwak L, McCarty N. Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma. PLoS One 8(8):e69126, 2013. e-Pub 2013. PMID: 23936317.
120. Phillip CJ, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V, Taverna P, Redkar S, Wang M, Stellrecht CM, Gandhi V. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol 6:92, 2013. e-Pub 2013. PMID: 24326130.
121. Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 8(10):e76781, 2013. e-Pub 2013. PMID: 24204673.
122. Fu W, Delasalle K, Wang J, Song S, Hou J, Alexanian R, Wang M. Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma. Am J Clin Oncol 35(6):562-5, 2012. e-Pub 2011. PMID: 21694573.
123. Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW, Wang M, Yi Q. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood 120(18):3783-92, 2012. e-Pub 2012. PMID: 22968454.
124. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple myeloma. Blood 120(16):3260-70, 2012. e-Pub 2012. PMID: 22932796.
125. Zhao L, Ji W, Ou G, Lv J, Liang J, Feng Q, Zhou Z, Wang M, Yin W. Risk factors for radiation-induced lung toxicity in patients with non-small cell lung cancer who received postoperative radiation therapy. Lung Cancer 77(2):326-30, 2012. e-Pub 2012. PMID: 22512813.
126. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab in patients with relapsed and refractory mantle cell lymphoma: a phase I/II clinical trial. Lancet Oncol 13(7):716-23, 2012. e-Pub 2012. PMID: 22677155.
127. Liu X, Guo W, Wu S, Wang L, Wang J, Dai B, Kim ES, Heymach JV, Wang M, Girard L, Minna J, Roth JA, Swisher SG, Fang B. Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells. Biochem Pharmacol 83(10):1456-64, 2012. e-Pub 2012. PMID: 22387047.
128. Sun L, Zhang L, Qian J, Yang J, Yi Q, Dong W, Wang M. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo. Leuk Res 36(3):363– 368, 2012. e-Pub 2011. PMID: 22000823.
129. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-6, 2012. e-Pub 2012. PMID: 22231283.
130. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL Jr, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH.. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118(9):2507-15, 2012. PMID: 21887685.
131. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber D, Wang M, Orlowski R, Thomas S, Shah J, Qureshi S, Dinh Y, Popat U, Anderlini P, Hosing C, Giralt S, Champlin R, Qazilbash M. Feasibility of autologous hematopoietic stem cell transplantation in patients aged ≥70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 2012. PMID: 21780997.
132. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE.. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23(6):1640-5, 2012. e-Pub 2011. PMID: 22015451.
133. Jung HJ, Chen Z, Wang M, Fayad L, Romaguera J, Kwak LW, McCarty N. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma (MCL) via manipulation of tissue transglutaminase activities. Blood 119(11):2568-78, 2012. PMID: 22294726.
134. Jung HJ, Chen Z, Fayad L, Wang M, Romaguera J, Kwak LW, McCarty N. Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma. Exp Hematol 40(2):107-118, 2012. PMID: 22024108.
135. Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R, Kwak L, Rustveld L, Du XL, Wang M.. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: A large population-based study. Cancer 118(15):3793-800, 2012. PMID: 22139816.
136. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS.. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 119(24):5661-70, 2012. e-Pub 2012. PMID: 22555973.
137. Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 158(6):739-48, 2012. PMID: 22845873.
138. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S.. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120(14):2817-25, 2012. PMID: 22833546.
139. Chen Z, Romaguera J, Wang M, Fayad L, Kwak LW, McCarty N.. Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production. Br J Haematol 159(2):243-6, 2012. PMID: 22924544.
140. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG, on behalf of the International Myeloma Working Group, International Myeloma Working Group, Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet-Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, Beksaç M, Belch A, Ben-Yehuda D, Bensinger B, Leif Bergsagel P, Bird J, Bladé J, Boccadoro M, Cavo M, Chanan-Khan A, Ming Chen W, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, García-Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen H, Jian H, Joshua D, Jurczyszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Lee JH, Leleu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Nari H, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N, Vincent Rajkumar S, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L, Miguel JS, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Broek IV, Vanderkerken K, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J.. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26(1):149-57, 2012. PMID: 21799510.
141. Weng J, Cha SC, Matsueda S, Alatrash G, Popescu MS, Yi Q, Molldrem JJ, Wang M, Neelapu SS, Kwak LW. Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes. Clin Cancer Res 17(18):5945-52, 2011. e-Pub 2011. PMID: 21813633.
142. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ, Orlowski RZ. Evidence of a Role for Activation of Wnt/β-catenin Signaling in the Resistance of Plasma Cells to Lenalidomide. J Biol Chem 286(13):11009-11020, 2011. e-Pub 2010. PMID: 21189262.
143. Hunsucker S, Valeria Magarotto V, Kornblau S, Wang M, Weber DM, Thomas SK, Shah J, Voorhees P, Xie H,Cornfeld M, Nemeth JA, Orlowski R. Blockade of interleukin-6 signaling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 152(5):579-92, 2011. PMID: 21241278.
144. Wen J, Feng Y, Bjorklund C, Wang M, Orlowski RZ, Shi Z, Liao B, OHare J, Zu Y, Schally A, Chang C. Luteinizing hormone-releasing hormone (LHRH)-I antagonist Cetrorelix inhibits myeloma cell growth in vitro and in vivo. Mol Cancer Ther 10(1):148-58, 2011. PMID: 21062912.
145. Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, Wang M, Sharma R, Yang D, Orlowski RZ.. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood 118(15):4140-9, 2011. PMID: 21844567.
146. Cao Y, Lan Y, Qian J, Zheng Y, Hong S, Li H, Wang M, Kwak LW, Lin D, Yang J, Yi Q.. Targeting cell surface β2 -microglobulin by pentameric IgM antibodies. Br J Haematol 154(1):111-21, 2011. PMID: 21554263.
147. Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang M, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G.. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol 86(6):484-7, 2011. PMID: 21477075.
148. Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant 16(8):1122-9, 2010. e-Pub 2010. PMID: 20178853.
149. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200-8, 2010. PMID: 20528872.
150. Harousseau JL, Dimopoulos MA, Wang M, Corso A, Chen C, Attal M, Spencer A, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 95(10):1738-44, 2010. PMID: 20460639.
151. Wang M, Delasalle K, Giralt S, Alexanian R. Rapid control of previously untreated multiple myeloma with bortezomib–lenalidomide– dexamethasone (BLD). Hematology 15(2):70-73, 2010. PMID: 20423566.
152. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE.. Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomarkers Prev 19(10):2445-52, 2010. PMID: 20805315.
153. Ross WA, Egwim CI, Wallace MJ, Wang M, Madoff DC, Lee JH. Outcomes in lymphoma patients with obstructive jaundice: a cancer center experience. Dig Dis Sci 55(11):3271-7, 2010. PMID: 20632106.
154. Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez A, Wang M, Weaver P, Hartig K, Kwak LW, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol 151(1):47-53, 2010. PMID: 20735402.
155. Qian Z, Zhang L, Cai Z, Sun L, Wang H, Yi Q, Wang M. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res 35(3):380-6, 2010. PMID: 21047686.
156. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene 30(11):1329-40, 2010. e-Pub 2010. PMID: 21057542.
157. Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M, Handy B, Lee JJ, Alexanian R.. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplantation 45(3):498-504, 2010. PMID: 19633690.
158. Chen Z, Ayala P, Wang M, Fayad L, Katz RL, Romaguera J, Caraway N, Neelapu SS, Kwak LW, Simmons PJ, McCarty N.. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Res 5(3):212-25, 2010. PMID: 20851072.
159. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15(6):718-23, 2009. e-Pub 2009. PMID: 19450756.
160. Wang M, Sun L, Qian J, Han X, Zhang L, Lin P, Yi Q. Cyclin D1 as a universally-expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia 23(7):1320-1328, 2009. PMID: 19225534.
161. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 15(7):812-816, 2009. PMID: 19539212.
162. Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 84(9):553-9, 2009. PMID: 19565649.
163. Qian J, Hong S, Wang S, Zhang L, Sun L, Wang M, Yang J, Kwak LW, Hou J, Yi Q. Myeloma cell line-derived, pooled heat shock proteins as a broad vaccine for immunotherapy of multiple myeloma. Blood 114(18):3880-9, 2009. PMID: 19654406.
164. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114(17):3625-8, 2009. PMID: 19710503.
165. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(31):5213-8, 2009. PMID: 19770379.
166. Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112(12):4445-4451, 2008. e-Pub 2008. PMID: 18799726.
167. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Lin P, Shi Y, Romaguera J, Kwak LW, Yi Q. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res 14(7):2154-2160, 2008. PMID: 18381957.
168. Zhou Y, Wang H, Fang W, Romaguera J, Zhang Y, Delasalle K, Kwak L, Yi Q, Du X, Wang M. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113(4):791-798, 2008. PMID: 18615506.
169. Wang M, Fayad L, Hagemeister F, McLaughlin P, Rodriguez A, Cabanillas F, Younes A, Neelapu S, Goy A, Zhou Y, Wang J, Beasley V, Kwak L, Kantarjian H, Romaguera J. Phase II trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed/refractory aggressive mantle cell lymphoma. Cancer 113(10):2734-2741, 2008. PMID: 18973182.
170. Wang M, Burau KD, Fang S, Wang H, Du XL. Ethnic variations in diagnosis, treatment, socioeconomic status and survival in a large population-based cohort of elderly patients with non-Hodgkin's Lymphoma. Cancer 113(11):3231-3241, 2008. PMID: 18937267.
171. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a Phase II randomized trial. Biol Blood Marrow Transplant 14(12):1401-7, 2008. PMID: 19041063.
172. Wang M, Han XH, Zhang L, Yang J, Qian JF, Shi YK, Kwak LW, Romaguera J, Yi Q. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 22(1):179-85, 2008. PMID: 17898787.
173. Stadtmauer EA, Lonial S, Vesole DH, Abonour R, Alsina M, Badros A, Comenzo R, Durie B, Giralt S, Hussein M, Jakubowiak A, Mehta J, Niesvizky R, Orlowski R, Siegel D, Singhal S, Vescio R, Wang M, Zangari M, Munshi NC. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol 5(10 Suppl 15):7-19, quiz 21-2, 2007. PMID: 18000495.
174. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 13(9):1066-72, 2007. e-Pub 2007. PMID: 17697969.
175. Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, Wan B, Kwak LW, Yu L, Yi Q. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 12(3):252-65, 2007. PMID: 17785206.
176. Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD, Epstein J, Kwak LW, Yi Q. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 110(5):1587-94, 2007. e-Pub 2007. PMID: 17515399.
177. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Samaniego F, Romaguera J, Yi Q. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood 109(12):5455-62, 2007. e-Pub 2007. PMID: 17317853.
178. Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 39(5):279-83, 2007. PMID: 17262062.
179. Rohatgi N, Du XL, Coker AL, Moye L, Wang M, Fang S. Chemotherapy and survival for patients with multiple myeloma: Findings from a large nationwide and population-based cohort. Am J Clin Oncol 30(5):540-548, 2007. PMID: 17921717.
180. Dang NH, Fayad L, McLaughlin P, Romaguera JE, Hagemeister F, Goy A, Neelapu S, Samaniego F, Walker P, Wang M, Rodriguez MA, Ton A, Pro B.. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin's lymphoma. Br J Haematol 138(4):502-505, 2007. PMID: 17608763.
181. Yang J, Zhang X, Wang J, Qian J, Zhang L, Wang M, Kwak LW, Yi Q. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood 110(8):3028-35, 2007. PMID: 17644731.
182. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD, Knight RD. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357(21):2133-42, 2007. PMID: 18032763.
183. Wang M, Giralt S, Delasalle K, Alexanian R. Bortezomib in combination with thalidomide-dexamethasone for previously untreated myeloma. Hematology 12(3):235-239, 2007. PMID: 17558699.
184. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad,, II, Couch RB. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis 194(10):1394-7, 2006. PMID: 17054068.
185. Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M, Yaccoby S, Kwak LW, Barlogie B, Yi Q. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell 10(4):295-307, 2006. PMID: 17045207.
186. Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 42(17):2976-81, 2006. PMID: 17008093.
187. Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D, Alexanian R, Talpaz M, Aggarwal B, Estrov Z. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer 93(1):70-80, 2005. PMID: 15970928.
188. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels B, Smith TL, Cabanillas F. High rate of durable remissions after treatment of newly diagnosed aggressive mantle cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate/cytarabine. J Clin Oncol 23(28):7013-23, 2005. PMID: 16145068.
189. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23(4):667-75, 2005. PMID: 15613697.
190. Wang M, Weber DM, Delasalle K, Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 79(3):194-7, 2005. PMID: 15981221.
191. Li Z, Ibrahim NK, Wathen JK, Wang M, Mante Menchu RP, Valero V, Theriault R, Buzdar AU, Hortobagyi GN. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer 101(7):1508-13, 2004. PMID: 15378497.
192. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22(20):4095-102, 2004. PMID: 15353540.
193. Leroy MJ, Degerman E, Taira M, Murata T, Wang LH, Movsesian M, Meacci E, Manganiello VC. Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells. Biochemistry 35(31):10194-10202, 1996. PMID: 8756484.
194. Kusui T, Hellmich MR, Wang LH, Evans RL, Benya RV, Battey JF, Jensen RT. Characterization of gastrin-releasing peptide receptor expressed in Sf9 insect cells by baculovirus. Biochemistry 34(25):8061-75, 1995.
195. Benya, RV, Wada, E, Battey, JE, Fathi, Z, Wang, LH, Mantey, SA, Coy, DH, Jensen, RT. Neuromedin B receptors retain functional expression when transfected into BALB 3T3 fibroblasts: Analysis of binding, stoichiometry, modulation by guanine nucleotide-binding proteins, and signal transduction and comparison with natively expressed receptors. Mol Pharm 42(2):8061-75, 1994.
196. Wang LH, Mantey SA, Lin JT, Frucht H, Jensen RT. Ligand binding, internalization, degradation and regulation by guanine nucleotides of bombesin receptor subtypes: A comparative study. Biochim Biophys Acta 1175(2):232-42, 1993. PMID: 8380344.
197. Wang LH, Battey JF, Wada E, Lin JT, Mantey S, Coy DH, Jensen RT. Activation of neuromedin B-preferring bombesin receptors on rat glioblastoma C-6 cells increases cellular Calcium and phosphoinositides. Biochem J 286(Pt2):641-8, 1992. PMID: 1326946.
198. Coy DH, Jiang NY, Kim SH, Moreau JP, Lin JT, Frucht H, Qian JM, Wang LH, Jensen RT. Covalently-cyclized agonist and antagonist analogues of bombesin and related peptides. J Biol Chem 266(25):16441-7, 1991.
199. Coy DH, Wang LH, Jensen RT. Bombesin agonists, partial agonists and antagonists-unexpected biological profiles among medicinally interesting analogues. Actualities de Chimie Therapeutique, Dix-Huiteme Serie (26 mes Recontes Interionales de Chimie Therapeutique, Montpellier France:157-165, 1990.
200. Rowley WH, Sato S, Huang SC, Collado-Escobar DM, Beaven MA, Wang LH, Martinez J, Gardner JD, Jensen RT. Cholecystokinin-induced formation of inositol phosphates in pancreatic acini. Am J Physiol 259:G655-65, 1990. PMID: 1699431.
201. Wang LH, Coy DH, Taylor JE, Jiang NY, Moreau JP, Huang SC, Frucht H, Haffar BM, Jensen RT. Des-Met carboxyl-terminally modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists or agonists. J Biol Chem 265(26):15695-703, 1990. PMID: 1697594.
202. Wang LH, Coy DH, Taylor JE, Jiang NY, Kim SH, Moreau JP, Huang SC, Mantey SA, Frucht H, Jensen RT. Desmethionine alkylamide bombesin analogues: A new class of bombesin receptor antagonists with potent antisecretory activity in pancreatic acini and antimitotic activity in Swiss 3T3 cells. Biochemistry 29(3):616-22, 1990. PMID: 1692477.
203. Coy DH, Taylor JE, Jiang NY, Wang LH, Huang SC, Qian JM, Moreau JP, Jensen RT. Developing receptor antagonists of neuropeptides-the bombesin/GRP and substance P systems. Peptides. Neuropeptides and Their Receptors, Alfred Benzon Symposium 29 29:376-385, 1990.
204. von Schrenck T, Wang LH, Coy DH, Villanueva ML, Mantey S, Jensen RT. Potent bombesin receptor antagonists distinguish receptor subtypes. Am J Physiol 259:G468-73, 1990. PMID: 2169207.
205. Coy D, Wang LH, Jiang NY, Jensen R. Short chain bombesin pseudopeptides with potent bombesin receptor antagonist activity in rat and guinea pig pancreatic acinar cells. Eur J Pharmacol 190:31-8, 1990. PMID: 1963850.
206. Coy DH, Taylor JE, Jiang NY, Kim SH, Wang LH, Huang SC, Moreau JP, Jensen RT. Short-chain bombesin receptor antagonists with IC50's for cellular secretion and growth approaching the picomolar region peptides. Proceedings of the 11th American Peptide Symposium Escom Science Publishers:65-8, 1990.
207. Sawyer TK, Jensen RT, Moran TH, Wang LH, Coy DH, Staples DG, DeVaux AE, Bradford VS. Structure activity relationships of cholecytokinin: Tyr[SO3H]: Substitutions Peptides. Chemistry, Structure and Biology:143-5, 1990.
208. Coy DH, Taylor JE, Jiang NY, Kim SH, Wang LH, Huang SC, Moreau JP, Gardner JD, Jensen RT. Short-chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity. J Biol Chem 264(25):14691-7, 1989. PMID: 2475489.

Invited Articles

1. Wang Y, Zhang LL, Champlin RE, Wang ML. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies. Clin Pharmacol Ther. e-Pub 2015. PMID: 25669675.
2. Zhang KJ, Wang M. Potential effects of CRM1 inhibition in mantle cell lymphoma. Chin J Cancer Res 24(4):374-87, 2012. PMID: 23357869.
3. Alexanian R, Delasalle K, Wang M, Thomas S, Weber D. Curability of multiple myeloma. Bone Marrow Res 2012:916479:916479, 2012. e-Pub 2012. PMID: 22675638.
4. Papathomas TG, Venizelos I, Dunphy CH, Said JW, Wang M, Campo E, Swerdlow SH, Chan JC, Bueso-Ramos CE, Weisenburger DD, Medeiros LJ, Young KH.. Mantle cell lymphoma as a component of composite lymphoma: clinicopathologic parameters and biologic implications. Hum Pathol 43(4):467-80, 2012. PMID: 22221705.
5. Wang M. Comparative mechanisms of action of proteasome inhibitors. Oncology Supplement(2):1-6, 2011.
6. Zhou Y, Garcia MK, Chang DZ, Chiang J, Lu J, Yi Q, Romaguera J, Delasalle K, Alexanian A, Guo Y, Forman A, Fang W, Wang M. Multiple myeloma, painful neuropathy, acupuncture?. Am J Clin Onc 32(3):319-325, 2009. PMID: 19887992.
7. Mullen EC, Wang M. Recognizing hyperviscosity syndrome in patients with Waldenstrom macroglobulinemia. Clin J Oncol Nurs 11(1):87-95, 2007. PMID: 17441400.
8. Zhou Y, Zhang L, Romaguera J, Delasalle K, Han X, Du X, Kwak L, Yi Q, Wang M. Immunotherapy in mantle cell lymphoma. Am J Hem 83(2):144-149, 2007. PMID: 17722077.
9. Wang M, Nguyen C, Alexanian A. Effective new agents for multiple myeloma. Case Studies in Myeloma, Physicians' Education Resource 2(2):1-7, 2006.
10. Wang M, Younes A. Testicular lymphoma: a mysterious link between the testis and the brain. Clin Lymphoma 3:173-4, 2002. PMID: 12521395.

Other Articles

1. Jain P, Dreyling M, Seymour JF, Wang M High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management. J Clin Oncol 38(36):4302-4316, 2020. PMID: 33074750.
2. Wang M, Jain P, Chi TL, Chen SE, Heimberger A, Weathers SP, Zheng L, Rao AV, Rossi JM Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2. J Immunother Cancer 8(2), 2020. PMID: 33067318.
3. Yang F, Markovic SN, Molina JR, Halfdanarson TR, Pagliaro LC, Chintakuntlawar AV, Li R, Wei J, Wang L, Liu B, Nowakowski GS, Wang ML, Wang Y Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis. JAMA Netw Open 5(7):1008-1019, 2020. PMID: 32766800.
4. Hill HA, Qi X, Jain P, Nomie K, Wang Y, Zhou S, Wang ML Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv 4(13):2927-2938, 2020. PMID: 32598477.
5. Zhang S, Kulkarni AA, Xu B, Chu H, Kourelis T, Go RS, Wang ML, Bachanova V, Wang Y Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. Blood Cancer J 10(3):33, 2020. PMID: 32144237.
6. Fu S, Wu CF, Wang M, Lairson DR Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review. Pharmacoeconomics 37(12):1421-1449, 2019. PMID: 31392666.
7. Jain P, Wang M Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol 94(6):710-725, 2019. PMID: 30963600.
8. Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. PMID: 31021376.
9. Zeng D, Desai A, Yan F, Gong T, Ye H, Ahmed M, Nomie K, Romaguera J, Champlin R, Li S, Wang M Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma). Am J Clin Oncol 42(3):304-316, 2019. PMID: 29419530.
10. Jurczak W, Dlugosz-Danecka M, Wang M Acalabrutinib for adults with mantle cell lymphoma. Expert Rev Clin Pharmacol 12(3):1-9, 2019. PMID: 30638402.
11. Ahmed M, Lorence E, Wang J, Jung D, Zhang L, Nomie K, Wang M Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma. Sci Signal 12(567), 2019. PMID: 30723172.
12. Srour SA, Lee HJ, Nomie K, Ye H, Chen W, Oriabure O, Romaguera J, Wang M Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma. Br J Haematol 181(4):561-564, 2018. PMID: 28369820.
13. Wang Y, Nowakowski GS, Wang M, Ansell SM Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma. J Hematol Oncol 11(1):57, 2018. PMID: 29685160.
14. Steiner RE, Romaguera J, Wang M Current trials for frontline therapy of mantle cell lymphoma. J Hematol Oncol 11(1):13, 2018. PMID: 29374487.
15. Ye H, Desai A, Zeng D, Nomie K, Romaguera J, Ahmed M, Wang M Smoldering mantle cell lymphoma. J Exp Clin Cancer Res 36(1):185, 2017. PMID: 29246179.
16. Huang XJ, Liu K, Ritchie D, Andersson B, Lu J, Hou J, Burguera AF, Wang J, Yeoh A, Yan C, Zhou D, Tan D, Kim DW, Wu D, Shpall E, Kornblau S, Neelapu S, Hongeng S, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Hagemeister F, Westin J, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Orlowski RZ, Chim CS, Mulligan S, Sanz M, Ozawa K, Parmar S, Issaragrisil S Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget 8(25):41620-41630, 2017. PMID: 28404929.
17. Zhang K, Desai A, Zeng D, Gong T, Lu P, Wang M Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting. Oncotarget 8(6):10748-10759, 2017. PMID: 27863374.
18. Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget 7(45):74380-74392, 2016. PMID: 27602582.
19. Ahmed M, Li L, Pinnix C, Dabaja B, Nomie K, Lam L, Wang M ATM mutation and radiosensitivity: An opportunity in the therapy of mantle cell lymphoma. Crit Rev Oncol Hematol 107:14-19, 2016. PMID: 27823642.
20. Ahmed M, Zhang L, Nomie K, Lam L, Wang M Gene mutations and actionable genetic lesions in mantle cell lymphoma. Oncotarget 7(36):58638-58648, 2016. PMID: 27449094.
21. Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, Fellowes VS, Hakim FT, Gress RE, Kochenderfer JN T cells expressing an anti-B-cell-maturation-antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128(13):1688-700, 2016. PMID: 27412889.
22. Lu J, Hou J, Liu KY, Parmar S, De La Fuente A, Andersson B, Yan C, Zhou D, Tan D, Ritchie D, Wu D, Shpall E, Laport GG, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Issaragrisil S, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Rosengarten R, Steuernagle J, Xiao JH, Orlowski R, Chim CS Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China. Leuk Lymphoma 57(7):1-5, 2016. PMID: 26887657.
23. Sanchez L, Wang Y, Siegel DS, Wang M Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol 9(1):51, 2016. PMID: 27363983.
24. Wang Y, Yang F, Shen Y, Zhang W, Wang J, Chang VT, Andersson BS, Qazilbash MH, Champlin RE, Berenson JR, Guan X, Wang M Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. J Natl Cancer Inst 108(3), 2016. PMID: 26582244.
25. Cheah CY, Seymour JF, Wang ML Mantle Cell Lymphoma. J Clin Oncol 34(11):1256-69, 2016. PMID: 26755518.
26. Li H, Hu J, Wu S, Wang L, Cao X, Zhang X, Dai B, Cao M, Shao R, Zhang R, Majidi M, Ji L, Heymach JV, Wang M, Pan S, Minna J, Mehran RJ, Swisher SG, Roth JA, Fang B Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget 7(3):3548-58, 2016. PMID: 26657290.
27. Wang M Winning the battle at the front lines: lenalidomide plus rituximab— a promising initial treatment for mantle cell lymphoma. ASCO POST, 2016.
28. Cheah CY, Fowler NH, Wang M Breakthrough therapies in B-cell non-Hodgkin lymphoma. Annals Onc, 2016.
29. Chen Y, Wang M, Romaguera J Current regimens and novel agents for mantle cell lymphoma. Br J Haematol 167(1):3-18, 2014. PMID: 24974852.
30. Desai M, Newberry K, Ou Z, Wang M, Zhang L Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective. Ther Adv Hematol 5(3):91-101, 2014. PMID: 24883181.
31. Hoeller S, Zhou Y, Kanagal-Shamanna R, Xu-Monette ZY, Hoehn D, Bihl M, Swerdlow SH, Rosenwald A, Ott G, Said J, Dunphy CH, Bueso-Ramos CE, Lin P, Wang M, Miranda RN, Tzankov A, Medeiros LJ, Young KH Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Hum Pathol 44(1):110-21, 2013. PMID: 22944294.
32. Desai M, Newberry KJ, Romaguera J, Zhang L, Ou Z, Wang M Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy. J Hematol Oncol 6:55, 2013. PMID: 23915913.
33. Tan CH, Wang M, Fu WJ, Vikram R Nodular extramedullary multiple myeloma involvement of the liver presenting as hypervascular lesions on CT. Ann Acad Med Singapore. Ann Acad Med Singapore 40(7):329-3, 2011. PMID: 21870026.
34. Ke XY, Wang YF, Yang YH, Wang LH Multiple myeloma: past, present and future. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16(2):231-239, 2008. PMID: 18426640.
35. Hou J, Wang M Current status and future directions in the treatment of multiple myeloma. Chin Med J (Engl) 120(19):1651-4, 2007. PMID: 17935663.
36. Wang M, Zhou Y, Zhang L, Nguyen CA, Romaguera J Use of bortezomib in B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 6(7):983-91, 2006. PMID: 16831071.
37. Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol 40(4):3-7, 2003. PMID: 15015890.

Editorials

1. Wang M. New kid on the block: ONC201 in NHL. Cell Cycle 14(22):0, 2015. PMID: 26102059.
2. Zhang L, Newberry KJ, Wang M. Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment. Expert Rev Clin Immunol 9(6):495-7, 2013. PMID: 23730878.
3. O’Brien SM, Wang M. Highlights in B-cell malignancies from the 2012 American Society of Hematology (ASH) Meeting. Clinical Advances in Hematology & Oncology 11(4 suppl6):1-19, 2013.
4. Wang M. Commentary on "Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait". Clin Adv Hem & Onc 3(12):3, 2005.

Abstracts

1. Yao Y, Wang M. Exploiting PRMT5, a metabolic and epigenetic regulator, as a novel therapeutic target in mantle cell lymphoma. AACR Annual Meeting 2020, 2020.
2. Jiang C, Wang M. Single-cell RNA-seq reveals heterogeneity, clonal evolution and strategies to overcome ibrutinib-venetoclax dual resistance in mantle cell lymphoma. AACR Annual Meeting 2020, 2020.
3. Kabadi SM, Goyal RK, Nagar SP, Davis KL, Le H, Du XL, Jain P, Wang M, Romaguera JE, Kaye JA. Overall Survival, Adverse Events, and Economic Burden in Medicare-Insured Patients with Mantle Cell Lymphoma Receiving Cancer-Directed Therapy. Blood (ASH Annual Meeting Abstract) 134(Suppl). e-Pub 2019.
4. Wang ML, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM. KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study. Blood (ASH Annual Meeting Abstract) 134(Suppl). e-Pub 2019.
5. Wang ML, Jain P, Lee HJ, Hagemeister FB, Samaniego F, Westin JR, Nastoupil LJ, Chen W, Nomie K, Zhang S, Moghrabi O, Zhao S, Kanagal-Shamanna R, Ok CY, Oriabure O, Nogueras González GM, Jung D, Navsaria L, Uy A, Pedersen A, Zhang L, Jiang C, Lei F, Yao Y, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Patel K, Yin CC, Avellaneda M, Badillo M, Fayad L, Neelapu SS, Fowler NH, Romaguera JE, Wang L. Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) – Results of Phase-II Window-1 Clinical Trial. Blood (ASH Annual Meeting Abstract) 134(Suppl). e-Pub 2019.
6. Zhang L, Guo H, Zhang H, Yao Y, Liu Y, Zhang S, Rui L, Wang L, Nomie K, Wang ML. Genetically Defined Metabolic Targets Overcome Ibrutinib Resistance in Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 134(Suppl 1), 2019.
7. Liu Y, Zhao S, Jiang C, Yao Y, Murfin KP, Grundman H, Zhang L, Nomie K, Wang L, Wang M. The Development of a Precision Medicine Platform to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 134(Suppl 1), 2019.
8. Nomie K, Kotlov N, Svekolkin V, Bagaev A, Cai Q, Falahat J, Moghrabi O, Frenkel F, Attaulakhanov R, Leeming A, Jung D, Hill H, Murfin KP, Chen Z, Hartig K, Badillo M, Jain P, Zhang L, Wang M. Tumor Microenvironment Molecular Signatures That Define Therapeutic Resistance in Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 134(Suppl 1), 2019.
9. Yao Y, Liu Y, Zhang H, Leeming A, McIntosh JM, Jain P, Zhang L, Nomie K, Wang ML. Identify AMPK-Mediated Autophagy and Oxphos As a Novel Metabolic Vulnerability for Targeted Therapy in Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 134(Suppl 1), 2019.
10. Jiang C, Zhang S, Huang S, Liu Y, Zhang R, Leeming A, McIntosh JM, Lee W, Nomie K, Wang L, Wang ML. Pdox Models Empower Preclinical Drug Evaluation and Mechanistic Studies Via Faithful Recapitulation of the Pathology, Complex Heterogeneity, Genetic-Transcriptomic Landscape, and Therapeutic Response of Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 134(Suppl 1), 2019.
11. Guo H, Zhang H, Nomie K, Zhang L, Murfin KP, Wang M. Establishment and characterization of a novel MYC/BCL2 double-hit high-grade B-cell lymphoma cell line HLA-3. AACR Annual Meeting 2019 79(13), 2019.
12. Wang M, Gordon LI, Palomba ML, Abramson JS, Andreadis C, Ghosh N, Lunning M, Maloney D, Farazi T, Garcia J, Xie B, Newhall K, Dehner C, Siddiqi T. Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001. Hematological Oncology 37(S2 Suppl):301-303, 2019.
13. Wang M, Jain P, Zhang S, Nomie K, Wang L, Oriabure O, Nogueras Gonzales G, Zhang L, Wagner-Bartak N, Hagemeister F, Samaniego F, Westin J, Lee HJ, Nastoupil L, Ok C, Kanagal-Shamanna R, Chen W, Thirumurthi S, Santos D, Badillo M, Fayad L, Neelapu S, Fowler N, Romaguera J. Ibrutinib with rituximab (IR) and short course R-HyperCVAD/MTX is very efficacious in previously untreated young pts with mantle cell lymphoma (MCL). 15-ICML 37(S2 Suppl):42-43, 2019.
14. Wang M, Ramchandren R, Chen R, Karlin L, Chong G, Jurczak W, Wu K, Bishton M, Collins G, Eliadis P, Peyrade F, Freise K, Sukbuntherng J, Lee Y, Dobkowska E, Fedorov V, Neuenburg J, Tam C. Results From the Safety Run-In Period of the SYMPATICO Study Evaluating Ibrutinib in Combination With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma. 15-ICML 37(S2 Suppl):333-335, 2019.
15. Strati P, Ahmed MA, Fowler NH, Hagemeister FB, Fayad L, Rodriguez MA, Samaniego F, Wang M, Westin J, Romaguera JE, Noorani M, Phansalkar K, Cheah C, Feng L, Davis RE, Nastoupil LJ, Neelapu SS. Prognostic value of baseline SUVmax in patients with advanced stage follicular lymphoma receiving frontline rituximab-based therapy. 2019 ASCO Annual Meeting 37(Suppl), 2019.
16. Anand K, Burns E, Sano D, Pingali SR, Westin J, Nastoupil LJ, Lee HJ, Samaniego F, Parmar S, Wang M, Hawkins M, Adkins S, Fayad L, Steiner R, Nair R, Ahmed S, Fowler NH, Neelapu SS, Iyer SP. Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS. 2019 ASCO Annual Meeting 37(Suppl), 2019.
17. Wang Y, Zhou S, Yang F, Nowakowski GS, Habermann TM, Wang M, Witzig TE. Efficacy of frontline treatment regimens in follicular lymphoma: A network meta-analysis of phase III randomized controlled trials. 2019 ASCO Annual Meeting 37(Suppl), 2019.
18. Yang F, Wang Y, Nowakowski GS, Wang M, Chintakuntlawar AV, Halfdanarson TR, Pagliaro LC, Wei J, Liu B, Molina JR, Markovic S. Association of sex, age and ECOG performance status with cancer immunotherapy efficacy in randomized controlled trials. 2019 ASCO Annual Meeting 37(Suppl), 2019.
19. Willis L, Tanzola M, Caracio R, Lucero KS, Shah BD, Woyach JA, Furman RR, Wang M, Brown JR. Targeting B-cell malignancies: Impact of an educational curriculum on BTK inhibitors. 2019 ASCO Annual Meeting 37(Suppl), 2019.
20. Zhang R, Lee W, Huang S, Liu Y, Leeming AH, McIntosh JM, Nomie KJ, Jiang CV, Wang M. Copanlisib and Volasertib overcome ibrutinib-venetoclax resistance via targeting PI3K-AKT signaling and G2/M cell cycle transition in mantle cell lymphoma. 15-ICML 37(S2 Suppl):126-127, 2019.
21. Jain P, Romaguera J, Nomie K, Zhang S, Wang L, Oriabure O, Wagner‐Bartak N, Zhang L, Hagemeister F, Samaniego F, Westin J, Lee HJ, Nastoupil L, Iyer S, Parmar S, Ok C, Kanagal‐Shamanna R, Chen W, Thirumurthi S, Santos D, Badillo M, Fayad L, Neelapu S, Fowler N, Wang M. Combination of ibrutinib with rituximab (IR) is highly effective in previously untreated elderly (>65 years) patients (pts) with mantle cell lymphoma (MCL) – phase II trial. 15-ICML 37(S2 Suppl):42, 2019.
22. Jain P, Kanagal‐Shamanna R, Zhang S, Ok C, Nogueras Gonzalez G, Gonzalez‐Pagan O, Ghorab A, Boddu P, Chen W, Ju Lee H, Nomie K, Fayad L, Westin J, Nastoupil L, Patel K, Ahmed S, Iyer SP, Parmar S, Champlin R, Neelapu S, Medeiros JL, Romaguera J, Fowler N, Wang L, Wang ML. Comprehensive analysis of prognostic factors, outcomes and mutation profile in patients with aggressive histology (blastoid/pleomorphic) or transformed mantle cell lymphoma. 15-ICML 37(S2 Suppl):238-239, 2019.
23. Strati P, Ahmed M, Fowler N, Hagemeister F, Fayad L, Rodriguez M, Samaniego F, Wang M, Westin JR, Romaguera J, Noorani M, Phansalkar K, Cheah C, Feng L, Davis RE, Nastoupil L, Neelapu SS. Prognostic value of pre-treatment PET scan in patients with follicular lymphoma receiving frontline therapy. 15-ICML 37(S2 Suppl):53-54, 2019.
24. Tam CS, Wang M, Simpson D, Opat S, Cull G, Munoz J, Phillips TJ, Kim W, Atwal S, Wei R, Huang J, Elstrom R, Trotman J. Updated Safety and Efficacy Data in the Phase 1 Trial of Patients with Mantle Cell Lymphoma (MCL) Treated with Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib (BGB-3111). 15-ICML 37(S2 Suppl):245-247, 2019.
25. Wang Y, Wang R, Zhang S, Song S, Jiang C, Han G, Wang M, Ajani J, Futreal A, Wang L. iTALK: an R Package to Characterize and Illustrate Intercellular Communication. bioRxiv The Preprint Server for Biology, 2019.
26. Nomie k, Zhang L, Yao y, Liu Y, Zhang S, Zhang H, Guo H, Ahmed M, Badillo M, Wang L, Wang M. Ibrutinib-Resistant Mantle Cell Lymphoma Undergoes Metabolic Reprogramming Towards Oxphos. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):41, 2018.
27. Sano D, Nastoupil LJ, Fowler NH, Fayad L, Hagemeister FB, Lee HJ, Samaniego F, Wang M, Rodriguez MA, Iyer SP, Parmar S, Steiner R, Nair R, Adkins S, Arafat S, Rao A, Vallejo L, Hawkins M, Chen Y, Westin JR, Neelapu SS. Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):96, 2018.
28. Wang W, Carrie F, Guo H, Lee J, Li Y, Sukhanova M, Sheng D, Venkataraman G, Mei M, Lu P, Gao A, Xia C, Jia L, Zhang L, Wang M, Andrade J, Xiaoyan Z, Wang YLL. Inhibition of B-Cell Receptor Signaling Disrupts Cell Adhesion in Mantle Cell Lymphoma Via RAC2. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):1369, 2018.
29. Ahmed M, Guo H, Zhang S, Sehgal L, Jain P, Kanagal-Shamanna R, Ok CY, Leeming A, Yao Y, Zhang L, Nomie K, Wang L, Wang M. Unravelling the Heterogeneity of Mantle Cell Lymphoma Ecosystem By Single Cell RNA Sequencing. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):4118, 2018.
30. Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Nogueras González GM, Ahmed M, Gonzalez-Pagan O, Ghorab A, Boddu PC, Chen W, Lee HJ, Badillo M, Nomie K, Fayad L, Nastoupil LJ, Champlin RE, Neelapu SS, Patel K, Medeiros LJ, Romaguera JE, Fowler NH, Wang L, Wang M. Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):1599, 2018.
31. Fowler NH, Jain P, Nastoupil LJ, Hagemeister FB, Forbes SG, Lagrone L, Fayad L, Lee HJ, Davis RE, Westin JR, Wang M, Neelapu SS, Samaniego F. Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R2) in Previously Untreated Follicular Lymphoma. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):1594, 2018.
32. Tam CS, Wang M, Simpson D, Opat S, Cull G, Munoz J, Phillips TJ, Kim WS, Hilger J, Huang J, Novotny W, Trotman J. Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):1592, 2018.
33. Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T, Morschhauser F, Panizo C, Shah BD, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Gouill SLE, Oberic L, Robak T, Dua R, Frigault MM, Izumi R, Nguyen D, Patel P, Yin M, Jurczak W. Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):2876, 2018.
34. Phillips TJ, Smith SD, Jurczak W, Robak T, Stevens D, Farber CM, Pagel JM, Maddocks KJ, Flinn IW, Jedrzejczak WW, Goy A, Zinzani PL, Zaucha J, Coleman M, Chen T, Lee SK, Liang W, Seto A, Wang M. Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL). Blood (ASH Annual Meeting Abstract) 132(Suppl 1):4144, 2018.
35. Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Ahmed M, Nava D, Badillo M, Nomie K, Patel K, Lee HJ, Hagemeister FB, Fayad L, Nastoupil LJ, Medeiros LJ, Neelapu SS, Romaguera JE, Fowler NH, Wang L, Wang M. Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):4151, 2018.
36. Yao Y, Liu Y, Guo H, Ahmed M, Bhuiyan S, Nomie K, Zhang L, Wang M. Metabolic Profiling Identifies De Novo Nucleotide Synthesis As a Potential Metabolic Vulnerability for Targeted Therapy Against Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):2945, 2018.
37. Ye H, Huang S, Jung D, Jiang C, Nomie K, Zhang L, Wang M. Simultaneous Inhibition of BCL-2 and PI3K Signaling Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):2950, 2018.
38. Zhang L, Zhang H, Guo H, Sun Y, Feng N, Marszalek JR, Ahmed M, Nomie K, Wang M. A Novel Patient-Derived Xenograft Model of Secondary CD20- CNS Lymphoma for Mechanistic and Therapeutic Exploration. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):1669, 2018.
39. Guo H, Yao Y, Zhang H, Lorence E, Ahmed M, Ping L, Nomie K, Zhang L, Wang M. FoxM1-Mediated Signaling Promotes the Progression of Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):4176, 2018.
40. Liang R, Wang JH, Liu F, Duan XH, Hao XC, Zhang L, Wang M, Liu X, Guo YH, Wang Z, Tang H, Yang L. Research of miR-30b in Cisplatin Resistance of Human NK/T Cell Lymphoma Lines SNK-6 and YTS Cells By Targeting CCL22. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):5302, 2018.
41. Jain P, Nastoupil LJ, Kanagal-Shamanna R, Nogueras González GM, Noorani M, Romaguera JE, Fayad L, Samaniego F, Westin JR, Medeiros LJ, Neelapu S, Wang M, Fowler NH. Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of 172 Patients. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):1600, 2018.
42. Fu S, Wang M, Zhao H, Li R, Lairson D, Giordano S, Zhao B, Du X. Effects of Rituximab, Bortezomib, and Bendamustine on the Survival in Medicare Beneficiaries with Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia 18:S273-S274, 2018.
43. Jiang C, Huang S, Liu Y, Nomie K, Zhang L, Wang M. Dual targeting of BTK and PLK1 causes lethal synergistic effects in mantle cell lymphoma. Cancer Research 78(13), 2018.
44. Ahmed M, Lorence E, Guo H, Huang S, Zhang V, Zhang H, Zhang L, Nomie K, Wang M. Pan-cancer Pathways Gene Expression Profiling in Mantle Cell Lymphoma Reveals Upregulation of DNA Damage Repair Genes in Ibrutinib-Resistant Tumor. American Association for Cancer Research 78(13), 2018.
45. Abramson JS, Gordon LI, Palomba ML, Lunning MA, Arnason JE, Forero-Torres A, Wang M, Maloney DG, Sehgal A, Andreadis C, Purev E, Solomon SR, Ghosh N, Albertson TM, Xie B, Garcia J, Siddiqi T. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. 2018 ASCO Annual Meeting 36(Suppl), 2018.
46. Barta SK, Rasco DW, Chen AI, Elkins S, Wang M, Denis LJ, Toker S, Usansky H, Reddy S, Rao NS. Clinical activity, safety and tolerability of ASN002, a dual JAK/SYK inhibitor, in patients with non-Hodgkin lymphoma (NHL), myeolfibrosis (MF), chronic lymphocytic leukemia (CLL) and solid tumors. 2018 ASCO Annual Meeting 36(Suppl), 2018.
47. Fu S, Wang M, Zhao H, Li R, Lairson DR, Giordano SH, Du XL. Effects of bendamustine, bortezomib, and rituximab on 1-year survival rates in elderly patients newly diagnosed with mantle cell lymphoma. 2018 ASCO Annual Meeting 36(Suppl), 2018.
48. Wang M, Locke FL, Munoz J, Goy A, Holmes HE, Siddiqi T, Flinn I, McSweeney PA, Reagan PM, Hill BT, Jacobson CA, Rizzieri DA, Heffner LT, Jaglowski SM, Miklos DB, Shaughnessy P, Unabia S, Rossi JM, Jiang Y, Jain RK. ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma. 2018 ASCO Annual Meeting, 2018.
49. Brudno J, Lam N, Wang M, Stroncek D, Maric I, Stetler-Stevenson M, Yuan C, Hartman S, Kanakry JA, Pavletic SZ, Feldman SA, Lawrence J, Patel R, Hansen B, Gress RE, Kochenderfer JN. T cells Genetically Modified to Express an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-prognosis Relapsed Multiple Myeloma. Journal of Clinical Oncology, 2018.
50. Abramson JS, Siddiqi T, Palomba ML, Gordon LI, Lunning MA, Arnason JE, Wang M, Forero-Torres A, Albertson T, Dehner C, Garcia J, Li D, Xie B, Maloney DG. High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): A defined composition CD19-directed CAR T-cell product with potential for outpatient administration. 2018 ASCO-SITC Clinical Immuno-Oncology Symposium 36(Suppl 5S), 2018.
51. Siddiqi T, Abramson JS, Palomba ML, Gordon LI, Lunning MA, Arnason JE, Wang M, Forero-Torres A, Maloney DG, Heipel M, Smith J, Brown W, Karimi M, Xie B, Li D, Albertson T, Garcia J, Dave K, DeVries T, Sutherland C. Correlation of patient characteristics and biomarkers with clinical outcomes of JCAR017 in R/R aggressive B-NHL (TRANSCEND NHL 001 study). 2018 ASCO-SITC Clinical Immuno-Oncology Symposium 36(Suppl 5S), 2018.
52. Byrd JC, Owen R, O'Brien SM, Brown JR, Hillmen P, Bitman B, Chernyukhin N, Hamdy A, Izumi R, Patel P, Schwartz-Sagi L, Tucker E, Fowler N, Streetly MJ, Wiestner A, Rule S, Wang M. Pooled Analysis of Safety Data from Clinical Trials Evaluating Acalabrutinib Monotherapy in Hematologic Malignancies. Blood (ASH Annual Meeting Abstract), 2017.
53. Romaguera JE, Lee HJ, Tarapore R, Prabhu VV, Allen JE, Schalop L, Zloza A, Ok CY, Badillo M, Wang M. Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment. Blood (ASH Annual Meeting Abstract) 130(5163), 2017.
54. Strati P, Oki Y, Fayad LE, Nastoupil L, Fowler NH, Hagemesiter FB, Kwak LW, Lee HJ, Wang M, Westin JR, Ruben C, Wesson E, Fanale MA. A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas. Blood (ASH Annual Meeting Abstract) 130(4074), 2017.
55. Becnel MR, Nastouil L, Davis RE, Hagemesiter FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Claret L, Forbes SG, Feng L, Samaniego F, Neelapu SS, Fowler N. 4. Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial. Blood (ASH Annual Meeting Abstract) 130(4040), 2017.
56. Manasanch EE, Lee HC, Patel KK, Weber DM, Lee HJ, Thomas SK, Chen W, Oriagure O, Badillo M, Graham V, Lei F, McCarthy MS, Orlowski RZ, Wang M. A Phase I/II Study of Pomalidomide and Dexamethasone with Growth Factor Support in Patients with Relapsed/Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstract) 130(3090), 2017.
57. Jain P, Kanagal-Shamanna R, Ghorab A, Nastoupil L, Fayad LE, Medeiros J, Hu S, Neelapu SS, Westin JJ, Oki Y, Wang M, Fowler NH. Characteristics, Treatments, and Outcomes of Patients with Lymphomatoid Granulomatosis—MD Anderson Cancer Center Experience. Blood (ASH Annual Meeting Abstract) 130(2852), 2017.
58. Zhang L, Nomie K, Zhang S, Liu Y, Guo H, Huang S, Wang J, Lopez E, Zhang H, Lorence EA, Merolle M, Balaji S, Ahmed M, Jiang C, Wang L, Wang M. Molecular Pathways Associated with Ibrutinib Resistance in Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 130(2738), 2017.
59. Huang S, Jiang C, Guo H, Wang J, Liu Y, Li CJ, Lopez E, Zhang H, Lorence EA, Merolle M, Balaji S, Ahmed M, Nomie K, Zhang L, Wang M. Resistance Mechanisms Underlying Venetoclax Resistance in Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 130(2749), 2017.
60. Guo H, Zhang H, Ahmed M, Liu Y, Huang S, Zhang V, Wang J, Lopez E, Lorence EA, Wang J, Balaji S, Merolle M, Jiang C, Nomie K, Wang M, Zhang L. FoxM1: A New Therapeutic Target for Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 130(1469), 2017.
61. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Arnason JE, Wang M, Forero A, Maloney DG, Albertson T, Garcia J, Li D, Xie B, Siddiqi T. High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort. Blood (ASH Annual Meeting Abstract) 130(581), 2017.
62. Jaing C, Huang S, Liu Y, Li C, Guo H, Wang J, Lopez E, Zhang H, Lorence EA, Merolle M, Balaji S, Ahmed M, Nomie K, Lin X, Zhang L, Wang M. Targeting the Paracaspase MALT1: A Potential Therapy to Overcome Ibrutinib Resistance in Relapsed/Refractory Mantle Cell Lymphoma Patients. Blood (ASH Annual Meeting Abstract) 130(574), 2017.
63. Gerson JN, Barta SK, Villa D, Gerrie AS, Li S, Medeiros J, Wang M, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Fenske TS, Rao SN, Maddocks KJ, Bond DA, Lansigan F, Burns T, Donovan AM, Mehta A, Reddy N, Landsburg DJ, Glenn M, Inwards DJ, Ristow K, Karmali R, Kaplan J, Umyarova E, Pulluri B, Amengual JE, Lue JK, Caimi P, Cohen JB, Calzada O, Handorf E, Anderson JK, Chapani P, Bachanova V, Rajguru S, Churnetski MC, Diefenbach C, Bast M, Kovach AE. Consolidation with Autologous Hematopoietic Cell Transplant in First Remission Improves Overall Survival in Younger Patients with Mantle Cell Lymphoma in the Rituximab Era. Blood (ASH Annual Meeting Abstract) 130(341), 2017.
64. Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, Hernandez-Rivas JA, Londhe A, Clow F, Deshpande S, Parisi L Wang M. Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis. Blood (ASH Annual Meeting Abstract) 130(151), 2017.
65. Wang M, Rule S, Zinzani PL, Goy A, Casasnovas RO, Smith SD, Damaj G, Doorduijin JK, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Gouill SL, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Slatter JG Jurczak W. Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study. Blood (ASH Annual Meeting Abstract) 130(155), 2017.
66. Tam CS, Simpson D, Opat S, Kin WS, Wang M, Cull G, Johnston PB, Munoz J, Lee WS, Marton P, Gottlieb D, Wang L, Huang J, Hilger J, Xue L, Ro S, Trotman J. Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma. Blood (ASH Annual Meeting Abstract) 130(152), 2017.
67. Siddiqi T, Abramson JS, Li D, Brown W, Devries T, Dave K, Garcia J, Palomba ML, Gordon LI, Lunning MA, Arnason JE, Wang M, Forero-Torres A, Maloney DG, Albertson T, Sutherland CL. Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017. Blood (ASH Annual Meeting Abstract) 130(193), 2017.
68. Brudno j, Lam N, Wang M, Stroncek D, Maric I, Stetler-Stevenson M, Yuan C, Hartman S, Kanakry JA, Pavletic SZ, Feldman SA, Lawrence J, Patel R, Hansen B, Gress RE, Kochenderfer JN. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor with a CD28 Costimulatory Moiety Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. Blood (ASH Annual Meeting Abstract) 130(Suppl 1):524, 2017.
69. Maloney DG, Abramson JS, Palomba ML, Gordon LI, Lunning MA, Arnason JE, Wang M, Forero A, Albertson T, Garcia J, Li D, Xie B, Siddiqi T. Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration. Blood (ASH Annual Meeting Abstract) 130(Suppl 1):1552, 2017.
70. Wang Y, Wang Y, Thanarajasingam G, Thompson CA, Habermann TM, Nowakowski GS, Wang M. Second Primary Malignancies in Patients with Non-Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstract) 130(Suppl 1):2152, 2017.
71. Wang Y, Wang Y, Wang M, Thanarajasingam G, Thompson C, Nowakowski G, Habermann T, Ansell S, Witzig T. Clinical Characteristics and Outcome of Transformed Diffuse Large B-Cell Lymphoma in the Rituximab Era: A SEER Database Analysis. Clinical Lymphoma, Myeloma & Leukemia, 2017.
72. Huang S, Bell T, Liu Y, Guo H, Li C, Ahmed M, Lam L, Zhang H, Chen Z, Wang ML, Zhang L, Nomie K. Preclinical examination of the effects of MT-3724, an engineered toxin body targeting CD20, in mantle cell lymphoma. AACR Annual Meeting 77(13 Suppl), 2017.
73. Wang M, Martin P, Phillips T, Goy A, Lossos IS, Rule S, Hamadani M, Ghosh N, Kuzma C, Reeder CB, Barnett E, Bravo MC, Schuster S. Efficacy and Safety of Lenalidomide in Mantle Cell Lymphoma Patients who Relapsed, were Refractory to, or Progressed after Treatment with Ibrutinib: The MCL-004 Study. 2016 EHA - 21st Congress, 2017.
74. Tam CS, Rule S, Le Gouill S, Vitolo U, Tsao LC, Cavazos N, Beaupre DM, Wang M. Phase 3 Study of Ibrutinib in Combination With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). Hematological Oncology 35(S2):421-422, 2017.
75. Rasco DW, O'Rourke TJ, Chen AI, Wang M, Tolcher AW, Rao NS, Denis LJ, Reddy S, Barta SK. Clinical activity, safety and tolerability of ASN002, a dual SYK/JAK inhibitor, in patients non-Hodgkin lymphoma (NHL) and solid tumors. 2017 ASCO Annual Meeting 35(Suppl), 2017.
76. Hu B, Loghavi S, Fayad L, Noorani M, Fowler NH, Hagemeister FB, Lee HJ, Nastoupil LJ, Neelapu SS, Fanale MA, Samaniego F, Turturro F, Wang M, Davis RE, Westin JR, Medeiros LJ, Oki Y. Outcomes of de novo CD5+ diffuse large b-cell lymphoma (DLBCL) in the rituximab (R) era. 2017 ASCO Annual Meeting 35(Suppl), 2017.
77. Chen W, Zeng D, Desai A, Badillo M, Feng L, Yan F, Nomie K, Ping L, Ye H, Liang Y, Lee H, Oki Y, Romaguera J, Wang M. Improved outcome for patients with relapsed/refractory mantle cell lymphoma (MCL) who stop ibrutinib +/− rituximab for reasons other than progression of disease. 14-ICML 35(S2 Suppl):360, 2017.
78. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Arnason JE, Forero-Torres A, Wang M, Albertson TM, Allen T, Sutherland C, Xie B, Garcia J, Siddiqi T. CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001). 2017 ASCO Annual Meeting 35(Suppl), 2017.
79. Wang M. Chemotherapy for MCL Debate: The Positive Side. Clinical Lymphoma, Myeloma & Leukemia, 2017.
80. Wang M, Lee HJ, Thirumurthi S, Chuang HH, Hagemeister, FB, Westin JR, Fayad LE, Samaniego F, Turturro F, Chen W, Oriabure O, Huang SY, Li S, Zhang L, Badillo M, Hartig KH, Ahmed M, Nomie K, Lam LT, Addison AA, Romaguera JE. Chemotherapy-Free Induction with Ibrutinib-Rituximab Followed By Shortened Cycles of Chemo-Immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: A Phase II Clinical Trial. Blood Journal, 2016.
81. Wang M, Martin P, Phillips T, Goy A, Lossos IS, Rule SA, Hamadani M, Ghosh N, Reeder CB, Barnett E, Casadebaig Bravo M, Schuster SJ. Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study. 58th ASH Annual Meeting 128(22):1786. e-Pub 2016.
82. Li CJ, Liu Y, Bell T, Wang J, Guo H, Ahmed M, Zhang H, Lam LT, Nomie K, Wang L, Zhang Liang, Wang M. Novel Bruton's Tyrosine Kinase Inhibitor Bgb-3111 Demonstrates Potent Activity in Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 128(5374), 2016.
83. Liu Y, Bell T, Zhang H, Sun Y, Li CJ, Feng N, Huang S, Guo H, Wang J, Ahmed M, Zhang V, Lam LT, Nomie K, Zhang L, Di Francesco ME, Marszalek J, Wang M. Targeting Oxphos Pathway Against Ibrutinib Resistance to Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 128(290), 2016.
84. Sathyanarayanan V, Oki Y, Issa AK, Ahmed MA, Noorani M, Fanale MA, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler N, Turturro F, Davis ER, Rodriguez A, Wang M, Feng L, Young KH, McDonnell TJ, Pinnix CC, Fayad LE, Westin JR. High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy-the University of Texas MD Anderson Experience. Blood (ASH Annual Meeting Abstract) 128(106), 2016.
85. Sun B, Fiskus W, Zhang L, Raina K, Coleman K, Winkler J, Qian Y, Crew A, Shen A, Saenz DT, Mill CP, Wang M, Crews C, Bhalla KN. Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma Cells. Blood (ASH Annual Meeting Abstract) 128(1058), 2016.
86. Wang M, Pasi KJ, Pabinger I, Kerlin BA, Kulkarni R, Nolan B, Liesner R, Brown SA, Hanabusa H, Tsao E, Winding B, Lethagen S, Jain N. Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia. Blood (ASH Annual Meeting Abstract) 128(3791), 2016.
87. Saksena A, Miao Y, Lin P, Wang M, Yin CC, Li J, Medeiros LJ, Li S. CD5 Negative Mantle Cell Lymphoma: Clinicopathologic Correlations and Outcome in 58 Cases. Blood (ASH Annual Meeting Abstract) 128(2964), 2016.
88. Jain P, Kanagal-Shamanna R, Lucas FS, Wang M, Romaguera JE, Fayad LE, Oki Y, Westin JR, Medeiros J, Fowler N. Characteristics, Outcome and Pattern of Mutations in Patients with Follicular Lymphoma Who Progressed on BTK Inhibitors (Ibrutinib and acalabrutinib). Blood (ASH Annual Meeting Abstracts) 128(2975), 2016.
89. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Medeiros J, Davis RE, Oki Y. The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 128(4153), 2016.
90. Huang S, Nastoupil LJ, Guo H, Bell T, Ahmed M, Li CJ, Wang J, Liu Y, Zhang V, Kim CR, Boyle JN, Lorence EA, Lam LT, Chen Z, Zhang H, Shuttleworth SJ, Nomie K, Wang M, Zhang L. Pre-Clinical Evaluation of the PI3K-p110β/δ Inhibitor KA2237 in Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 128(1837), 2016.
91. Huo H, Huang S, Liu Y, Li CJ, Wang J, Zhang V, Ahmed M, Lam LT, Zhang H, Nomie K, Zhang L, Wang M. Genetic and Molecular Characterization of Ibrutinib-Resistant Mantle Cell Lymphoma: Designing Innovative Therapeutic Strategies. Blood (ASH Annual Meeting Abstract) 128(1838), 2016.
92. Bell T, Zhang H, Ahmed M, Guo H, Li CJ, Liu Y, Lam LT, Chen Z, Wang J, Zhang V, Nomie K, Zhang L, Wang M. Patient-Derived Xenograft Model in B-Cell Lymphoma: A Platform for a Personalized Clinical Trial. Blood (ASH Annual Meeting Abstract) 128(1839), 2016.
93. Boyle JN, Kim CR, Guo H, Bell T, Huang S, Li CJ, Liu Y, Zhang H, Wang J, Zhang V, Ahmed M, Lam LT, Nomie K, Zhang L, Zeng D, Wang M. CUDC-907: An Oral HDAC/PI3K Dual Inhibitor with Strong Preclinical Efficacy in MCL Model. Blood (ASH Annual Meeting Abstract) 128(4183), 2016.
94. Simar KA, Sathyanarayanan V, Issa AK, Ahmed MA, Noorani M, Fanale MA, Oki Y, Hagemeister FB, Neelapu SS, Nastoupil L, Fowler N, Turturro F, Davis RE, Rodriguez MA, Wang M, Feng L, Young KH, McDonnell TJ, Pinnix CC, Fayad LE, Westin JR. Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience. Blood (ASH Annual Meeting Abstract) 128(4208), 2016.
95. Nooka AK, Wang M, Yee AJ, Thomas SK, O'Donnell EK, Shah JJ, Kaufman JL, Peterkin D, Lonial S, Richardson PG, Raje N. Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Blood (ASH Annual Meeting Abstract) 128(2124), 2016.
96. Avet-Loiseau, Fonseca R, Dimopoulos MA, Spicka I, Masszi T, Hajek R, Rosinol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos M, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Obreja M, Moreau P. Efficacy and Safety by Cytogenetic Risk Status: Phase 3 Study (ASPIRE) of, 2016.
97. Bhalla K, Sun B, Fiskus W, Zhang L, Saenz D, Mill C, Wang M. Novel BRD4-Degrading Proteolysis Targeting Chimera (PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma (MCL) Cells. Clinical Lymphoma, Myeloma & Leukemia, 2016.
98. Zhang L, Pham L, Zhang H, Xie J, Tao W, Bell T, Chen Z, Fang B, Wang M, Nomie K. B-cell lymphoma patient-derived xenograft models: The road to personalized therapy. AACR Annual Meeting 2016 22(16 Suppl), 2016.
99. Zhang L, Pham L, Zhang H, Xie J, Tao W, Bell T, Chen Z, Nomie K, Fang B, Wang M. Overcoming primary ibrutinib resistance in mantle cell lymphoma. AACR Annual Meeting 2016 76(14 Suppl), 2016.
100. Lee HJ, Andreeff M, Benes C, Allen JE, Lee S, Oster W, Wang M. First-in-class Small Molecule ONC201 in B-cell Malignancies. 2016 ASCO Annual Meeting 34(Suppl), 2016.
101. Dimopoulos MA, Stewart KA, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Obreja M, Aggarwal S, Moreau P, Palumbo A. Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis of Response and Progression-Free Survival Hazard Ratio Over Time. 21st EHA Conference. e-Pub 2016.
102. Rule S, Dreyling M, Hess G, Auer R, Kahl Brad, Cavazos, N, Liu B, Clow F, Goldberg J, Beaupre D, Vermeulen J, Wildgust M, Wang M. Overall Survival Outcomes in Patients with Mantle Cell Lymphoma Treated with Ibrutinib in a Pooled Analysis of 370 Patients from Three International Open Label Studies. 21st EHA Conference. e-Pub 2016.
103. Issa A, Sathyanarayanan V, Fanale MA, Oki Y, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler NH, Turturro F, Noorani M, Ahmed MA, Davis RE, Rodriguez MA, Wang M, Feng L, Young KH, McDonnel T, Pinnix CC, Fayad L, Westin JR. Outcomes of Diffuse Large B-cell Lymphoma with MYC and/or BCL2 Protein Expression Treated with Intensive Chemotherapy. 2016 ASCO Annual Meeting. e-Pub 2016.
104. Locke FL, Wang M, Siddiqi T, Castro JE, Shah BD, Lee HJ, Budde LE, Choi MY, Anasetti C, Champlin RE, Forman SJ, Kipps TJ, Bot A, Jiang Y, Elias M, Wiezorek JS, Go WY. ZUMA-2: A phase 2 multicenter study evaluating the efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with relapsed/refractory mantle cell lymphoma (r/r MCL). 2016 ASCO Annual Meeting. e-Pub 2016.
105. Ali SA, Shi V, Wang M, Stroncek D, Maric I, Brudno JN, Stetler-Stevenson M, Rose JJ, Feldman S, Hansen B, Hakim FT, Gress RE, Kochenderfer JN. Remissions of multiple myeloma during a first-in-humans clinical trial of T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor. Blood (ASH Annual Meeting Abstract) 126(23):LBA-1, 2015.
106. Chihara D, Ahmed MA, Oki Y, Westin JR, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez A, Fowler N, Wang M, Fayad LE, Davis RE, Nastoupil L. Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL). 57th Annual ASH Meeting & Exposition. e-Pub 2015.
107. Chen C, Garzon R, Gutierrez M, Jacoby MA, Brown P, Flinn I, Stone RM, Savoie ML, Baz R, Gabrail NY, Wang M, Martin P, Siegel D, Mau-sorensen M, Andreef M, Marshall T, Saint-Martin JR, Carlson R, Shacham S, Kauffman M, Kuruvilla J. Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330). Blood (ASH Annual Meeting Abstracts) 126(258), 2015.
108. Pham L, Zhang L, Tao W, Zhao D, Zhang H, Xie J, Wang J, Nomie K, Wang M. 4. Developing Novel Therapeutic Strategies to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 126(707), 2015.
109. Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, Hajek R, Rosinol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Tonda M, Obreja M, Moreau P. 5. Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire. Blood (ASH Annual Meeting Abstracts) 126(731), 2015.
110. Jain P, Patel KP, Futreal A, Gumbs C, Hu S, Ramos CB, Wang M, Romaguera J, Fayad LE, Orlowski RZ, Medeiros J, Fowler N. Clinico-Pathological Characteristics, Treatments and Outcomes of Patients with Dendritic Cell Sarcoma (DS). Blood (ASH Annual Meeting Abstracts) 126(2700), 2015.
111. Sun B, Fiskus W, Saenz DT, Krieger S, Zhang L, Parmar S, Wang M, Bhall KN. 9. BET Protein Bromodomain Antagonist-Based Combinations Exert Synergistic Pre-Clinical Activity Against Ibrutinib-Sensitive or -Resistant Human Mantle Cell Lymphoma (MCL) Cells. Blood (ASH Annual Meeting Abstracts) 126(3704), 2015.
112. Wang Y, Wagner-Bartak N, Zhou S, Fowler N, Dela Rosa ML, Zhao D, Romaguera JE, Neelapu SS, Hagemeister FB, Fanale MA, Oki Y, Shah JJ, Thomas SK, Hosing CM, Zhang L, Badillo M, Chen W, Cai Q, Zou D, Champlin RE, Fayad LE, Lee HJ, Wang M. Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial. Blood (ASH Annual Meeting Abstracts) 126(3969), 2015.
113. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguea A, Wang M, Fowler N, Miranda RN, Hosing CM, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL. Blood (ASH Annual Meeting Abstracts) 126(3984), 2015.
114. Wang B, Zhang L, Pham L, Tao W, Zhang H, Xie J, Chen W, Cai Q, Zou D, Zhao D, Sun X, Liang R, Wang J, Nomie K, Fowler N, Wang M. The Identification of Novel Therapies for the Treatment of Follicular Dendritic Cell Sarcoma. Blood (ASH Annual Meeting Abstract) 125(5126), 2015.
115. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen J, Wang Z, Ma W, Lee H, Orlowski RZ, Sarbassov DD, Neelapu SS, McDonnell TJ, Miranda RN, Wang W, Kantarjian HM, Konopleva M, Davis RE, Andreeff M. ONC201 Induces p53-Independent Apoptosis and Abrogates Stem Cell Function in Hematological Malignancies By Induction of ATF4 through Integrated Stress Response. Blood (ASH Annual Meeting Abstract) 126(2051), 2015.
116. Nooka AK, Wang W, Yee AJ, Thomas SK, O'Donnell EK, Shah JJ, Kaufman JL, Lonial S, Richardson PG, Raje NS. Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Blood (ASH Annual Meeting Abstract) 126(4246), 2015.
117. Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Tonda M, Obreja M, Moreau P. Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391). Blood (ASH Annual Meeting Abstract) 126(23):731, 2015.
118. Shah JJ, Feng L, Thomas SK, Weber D, Wang M, Manasanch EE, Mendoza K, Orlowski RZ. Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood (ASH Annual Meeting Abstract) 126(23):376, 2015.
119. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 126(23):2738, 2015.
120. Shah JJ, Feng L, Weber D, Thomas SK, Wang M, Turturro F, Qazilbash MH, Shah N, Bashir O, Popat UR, Manasanch EE, Munoz SC, Landry A, Mendoza K, Nieto Y, Champlin RE, Orlowski RZ. Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood (ASH Annual Meeting Abstract) 126(23):3155, 2015.
121. Pinnnix CC, Dabaja BS, Milgrom S, Smith G, Abou Z, Shank J, Romaguera J, Turturro F, Fowler N, Fayad L, Nastoupil L, Westin J, Neelapu S, Rodriguez MA, Fanale MA, Hagemesiter F, Lee, HJ, Oki Y, Wang M, Samaniego F, Morrell GG, Chi L, Esmaeli B. Ultra Low Dose Radiation Therapy for the Definitive Management of Ocular Adnexal B-Cell Lymphoma, 2015.
122. Poggesi I, Sardu ML, Marostica E, Sukbuntherng J, Chang BY, de Jong J, de Trixhe XW, Vermeulen A, De Nicolao G, O'Brien SM, Byrd JC, Advani RH, James DF, Deraedt W, Beaupre D, Wang M. Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies. AACR Annual Meeting 2014 21(17 Suppl), 2015.
123. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, Sarbassov DD, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff M. First-in-class Anti-tumor Agent ONC201 Induces Apoptosis in Hematological Malignancies with Wild Type and Mutant p53. Clinical Lymphoma, Myeloma & Leukemia, 2015.
124. Wang M, Lee HJ, Chuang H, Hagemeister FB, Westin JJ, Fayad LE, Samaniego F, Turturro F, Chen W, Zhang L, Badillo M, Dela Rosa M, Addison A, Romaguera JE. Ibrutinib in combination with rituximab for relapsed mantle cell lymphoma: An update from a Phase II clinical trial, 2015.
125. Wang Y, Dela Rosa M, Zhou S, Badillo M, Addison A, Zhang L, Lee HJ, Romaguera JE, Wang M. Lenalidome in combination with rituximab for relapsed or refractory mantle cell lymphoma: Updated analysis of a phase 2 trial. 2015 ASCO Annual Meeting 33(Suppl), 2015.
126. Wang Y, Shen Y, Yang F, Sanchez LJ, Guan X, Tsu-Shih Chang V, Wang M. Rituximab maintenance Therapy in B-cell lymphoma: A meta-analysis. 2015 ASCO Annual Meeting 33(Suppl), 2015.
127. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Yasuhiro. Phase II study of Hyper-CVAD with pegylated liposomal doxorubicin alternating with methotrexate and cytarabine (HCVIDD/MA) in patients with newly diagnosed T- and NK-cell lymphoma (T/NKCL). 2015 ASCO Annual Meeting 33(Suppl), 2015.
128. Garzon R, Wang M , Kuruvilla J, Gutierrez M, Savoie L, Mau-Sørensen M, Flinn I, Baz R, Martin P, Gabrail N, Goy A, Brown P, Rashal T, Carlson R, Elloul S, Friedlander S, Saint-Martin J, Frenkel R, Raza-Mirza M, Norori S, Shacham S, Kauffman M, Wagner-Johnston N. Selinexor shows activity in double-hit diffuse large B-cell lymphoma in pre-clinical models and in patients with relapsed/refractory double-hit DLBCL. 13-ICML 33:179-180, 2015.
129. Lee HJ, Kim P, Badillo M, Romaguera J, Wang M. Atrial Fibrillation in Ibrutinib Treated Relapsed Mantle Cell Lymphoma, Clinical and Laboratory Analysis of Risk Factors. 13-ICML 33:208, 2015.
130. Ahmed MA, Chihara D, Vargas N, Ma L, Fayad LE, Oki Y, Hagemeister FB, Romaguera JE, Turturro F, Fowler N, Rodriguez MA, Samaniego F, Fanale MA, Nastoupil L, Wang M, Lee HJ, Kwak LW, Noorani M, Davis RE, Westin JR, Neelapu SS. Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma After Second Salvage Therapy: MD Anderson Experience. 13-ICML 33:279-280, 2015.
131. Balasubramanian S, Schaffer M, Deraedt W, Davis C, Stepanchick E, Aquino R, Yuan Z, Kranenburg B, Avivi I, Dreyling M, Rule S, Wang M, Zhuang SH, Rizo A, Lenz G. Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL). Blood (ASH Annual Meeting Abstracts) 124(21), 2014.
132. Wang M, Goy A, Martin P, Ramchandren R, Alexeeva J, Popat R, Avivi I, Advani R, Le Gouill S, Horowitz N, Yuan Z, Kranenburg B, Rizo A, Zhuang SH, Deraedt W, Rule S. Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy. Blood (ASH Annual Meeting Abstracts) 124(21), 2014.
133. Wang M, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani R, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson PW, Spurgeon SE, Zhang L, Baher L, Cheng M, Beaupre DM, Blum KA. Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study. Blood (ASH Annual Meeting Abstracts) 124(21), 2014.
134. Pham LV, Tamayo AT, Pogue E, G Lu, Challagundla P, Jorgensen JL, Zhang L, Wang M, Ford RJ. The Tumor Microenvironment in Mantle Cell Lymphoma (MCL): Novel Targets to Overcome Chemo-Resistance in MCL. Blood (ASH Annual Meeting Abstract) 124(21):494, 2014.
135. Wang M, Hagemeister F, Westin JR, Fayad L, Samaniego F, Turturro F, Chen W, Zhang L, Badillo M, DeLa Rosa M, Addison A, Kwak LW, Romaguera JE. Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial. Blood (ASH Annual Meeting Abstract) 124(21):627, 2014.
136. Ahmed MA, Fowler N, Ma L, Noorani M, Phansalkar K, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez A, Samaniego F, Fanale M, Wang M, Oki Y, Turturro F, Westin JR, Kwak LW, Nastoupil LJ, Cheah C, Feng L, Rohren EM, Davis RE, Neelapu SS. SUVmax on Pre-Treatment FDG PET Scan Is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Threapy. Blood (ASH Annual Meeting Abstract) 124(21):1629, 2014.
137. Park H, Zhao D, Tsourdinis G, Ou Z, Tamayo AT, Ford RJ, Fang B, Pham LV, Zhang L, Wang M. STAT3 Activation Is Preceded By Two Independent Pathways (BCR-BTK and IL6-JAK) in Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 124(21):3028, 2014.
138. Chen Y, Rodriguez MA, Feng L, Bi W, Zhang L, Wang M. Peripheral Absolute Neutrophil, Mmonocyte and Lymphocyte Counts and Clinical Ooutcome in Diffuse Large B-Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 124(21):4416, 2014.
139. Oki Y, Fanale MA, Romaguera JE, Fayad L, Fowler N, Copeland ARM, Samaniego F, Kwak LW, Neelapu SS, Wang M, Feng L, Younes A. Phase II Study of an AKT Inhibitor MK2206 in Patients with Relapsed or Refractory Lymphoma. Blood (ASH Annual Meeting Abstract) 124(21):3093, 2014.
140. Zhang L, Zhang H, Zhao D, Tsourdinis G, Park H, Tamayo AT, Pham LV, Ford RJ, Fang B, Wang M. Anti-CD20 and B-Cell Receptor-Mediated Growth Inhibition and Apoptosis: A Preclinical Study of Ibrutinib and Rituximab Combination Therapy in Mantle Cell Lymphoma in Vitro and in Vivo. Blood (ASH Annual Meeting Abstract) 124(21):1774, 2014.
141. Tsourdinis G, Park h, Sun L, Fokt I, Jayakumar A, Zhang H, Cai Q, Zou D, Fang B, Priebe W, Wang M, Zhang L. Potent Inhibition of the Growth and Induction of Apoptosis of Mantle Cell Lymphoma By the Novel Anthracycline Berubicin in Vitro and in Vivo. Blood (ASH Annual Meeting Abstract) 124(21):3106, 2014.
142. Siegel DS, Berdeja JG, Infante JR, Kaufman JL, Wang M, Martin TG, Niesvizky R, Reu FJ, Jagannath S, Rajangam K, Huang M, Vij R. Updated Results from a Phase 2 Extension Study of Patients with Multiple Myeloma or Solid Tumors Previously Enrolled in Carfilzomib Company-Sponsored Phase 1 and 2 Clinical Trials (PX-171-010). Blood (ASH Annual Meeting Abstract) 124(21):2134, 2014.
143. Wang Y, Zhang W, Yang F, Guan X, Kothari N, Chang V, Wang M. Bortezomib-Containing Regimens for Multiple Myeloma Maintenance Therapy: a Meta-Analysis. Blood (ASH Annual Meeting Abstract) 124(21):3473, 2014.
144. Wang Y, Yang F, Zhang W, Guan X, Kothari N, Chang V, Wang M. The Efficacy and Safety of Immunomodulatory Drugs in Multiple Myeloma Maintenance Therapy: Results of a Meta-Analysis. Blood (ASH Annual Meeting Abstract) 124(21):3477, 2014.
145. Wang M, Nooka AK, Yee AJ, Thomas SK, O'Donnell E, Shah J, Weber DM, Kaufman JL, Lonial S, Avigan D, Raje N. Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Blood (ASH Annual Meeting Abstract) 124(21):4737, 2014.
146. Chen Z, Orlowski RZ, Wang M, Kwak L,McCarty N. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. AACR Annual Meeting 2014 21(17 Suppl), 2014.
147. Thomas SK, Melendez G, Feng L, Wang M, Neelapu SS, Shah JJ, Orlowski RZ, Weber DM. Phase I trial of pomalidomide (P) in patients (pts) with relapsed and/or refractory (R/R) Waldenström's macroglobulinemia (WM). J Clin Oncol 32, 2014.
148. Thomas SK, Mendoza TR, Dougherty PM, Williams LA, Wang XS, Prasad S, Shah N, Shah JJ, Wang M, Weber DM, Orlowski RZ, Giralt S, Cleeland CS. A phase 2 trial of minocycline versus placebo to prevent neuropathy in patients (pts) with multiple myeloma (MM). J Clin Oncol 32, 2014.
149. Nastoupil LJ, Neelapu SS, Samaniego F, Hagemeister FB, Romaguera JE, Kwak LW, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, McLaughlin P, Fowler N. 10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study. J Clin Oncol 32, 2014.
150. Tsourdinis G, Park H, Sun L, Fokt I, Jayakumar A, Zhang H, Cai Q, Zou D, Fang B, Priebe W, Wang M, Zhang L. Potent Inhibition of the Growth and Induction of Apoptosis of Mantle Cell Lymphoma By the Novel Anthracycline Berubicin in Vitro and in Vivo. Blood 124(21):3106, 2014.
151. Samaniego F, Sehgal L, Braun FK, Berkova Z, Romaguera JE, Wang M, Rodriguez MA, Neelapu SS, Mathur R. Molecular Signatures of Tumor-Initiating Cells Unveil Wnt Pathway As a Therapeutic Target in Mantle Cell Lymphoma. Blood 124(21):2148, 2014.
152. Phansalkar K, Ahmed MA, Fowler N, Ma L, Noorani M, Lee ST, Feng L, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez A, Samaniego F, Fanale MA, Wang M, Oki Y, Turturro F, Westin JR, Nastoupil LJ, Kwak LW, Davis RE, Neelapu SS. R-Bendamustine Vs R-CHOP As Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis. Blood 124(21):3048, 2014.
153. Brett LK, Axelrod M, Ou Z, Zhang L, Gordon V, Lopez ER, Tamayo AT, Ford RJ, Pham LV, Weber MJ, Williamsn ME, Wang M. Drug Screening Reveals That Ibrutinib (PCI-32765) Exhibits Synergy With BCL-2 and Proteasome Inhibitors In Models Of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 122(21), 2013.
154. Vij R, Wang M, Jagannath S, Niesvizky R, Jakubowiak AJ, Kavalerchik E, Huang M, Siegel DS. Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 122(21), 2013.
155. Lopez ER, Dominici EM, Vang MT, Tamayo AT, Ou Z, Rollo A, Zhang L, Wang J, Strickland LM, Kirk CJ, Kauffman M, Shacham S, Wang M, Pham LV, Ford RJ. Selective Inhibitor Of Nuclear Exports (SINE) KPT-330 In Combination With The Novel Proteasome Inhibitor Carfilzomib As a Novel Therapeutic Regimen For Treating Aggressive B-Cell Lymphomas. Blood (ASH Annual Meeting Abstracts) 122(21), 2013.
156. Ou Z, Pham LV, Vang MT, Zhang L, Wang J, Strickland LM, Lopez ER, Dominici EM, Rollo A, Tamayo AT, Ford RJ, Wang M. Targeting BCR Activated STAT3 By Ibrutinib In Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 122(21), 2013.
157. Pham LV, Vang MT, Tamayo AT, Ou Z, Rollo A, Zhang L, Dominici EM, Lopez ER, Pham J, Wang J, Strickland LM, Wang M, Ford RJ. The Role Of Mir-155 In Controlling Key Growth and Survival Pathways In ABC-Subtype DLBCL. Blood (ASH Annual Meeting Abstracts) 122(21), 2013.
158. Dominici EM, Lopez ER, Vang MT, Tamayo AT, Ou Z, Rollo A, Zhang L, Wang J, Strickland LM, Wang M, Ford RJ, Pham LV, Kirk CJ. Carfilzomib, a Second-Generation Proteasome Inhibitor, In Combination With The Btk Inhibitor Ibrutinib As a Novel Therapeutic Regimen For Treating Double Hit DLBCL. Blood (ASH Annual Meeting Abstracts) 122(21), 2013.
159. Zhang L, Ou Z, Wang J, Dominici EM, Zhang H, Ford RJ, Wang M, Pham LV. Ibrutinib Overcomes Carfilzomib Resistance In Immunoproteasome-Deficient Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 122(21), 2013.
160. Alagappan A, Shah RA, Thomas SK, Weber DM, Wang M, Alexanian R, Orlowski RZ, Shah JJ. Feasibility and Activity Of Bortezomib-Based Therapy In Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Carfilzomib. Blood (ASH Annual Meeting Abstracts) 122(21), 2013.
161. Romaguera RE, Fanale MA, Samaniego F, Fayad LE, Hagemeister FB, McLaughlin P, Rodriguez MA, Weaver P, Hartig K, Badillo M, Kwak LW, Younes A, Pro B, Wang M. Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL). Blood (ASH Annual Meeting Abstracts) 122(21), 2013.
162. Shah RA, Mohite S, Baladandayuthapani V, Thomas SK, Weber DM, Wang M, Alexanian R, Qazilbash MH, Popat UR, Champlin RE, Shah N, Bashir Q, Parmar S, Nieto Y, Ahmed S, Orlowski RZ, Shah JJ. Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia. Blood (ASH Annual Meeting Abstracts) 122(21), 2013.
163. Oki Y, Noorani M, Davis RE, Neelapu SS, Rodriguez A, Hagemeister FB, Folwer N, Wang M, Fanale MA, Samaniego F, Dabaja BS, Pinnix C, Kwak LW, Romaguera JE, Khouri I, Westin JR, Fayad LE. Double Hit Lymphoma: M.D. Anderson Experience. Blood (ASH Annual Meeting Abstracts) 122(21), 2013.
164. Orlowski RZ, Zaman S, Thomas SK, Alexanian R, Shah JJ, Weber DM, Wang M, Holloway AN, Baladandayuthapani V, Lin HY, Fu M, Stellrecht CM, Morales de Partovi C, Gandhi V. Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM). Blood (ASH Annual Meeting Abstracts) 122(21), 2013.
165. Kongtim P, Qazilbash M, Shah JJ, Orlowski RZ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin RE, Parmar S. Autologous Stem Cell Transplantation Improves Survival For High Risk Cardiac Amyloidosis. Blood (ASH Annual Meeting Abstracts) 122(21), 2013.
166. Nieto Y, Shah N, Popat UR, Jones RB, Bashir Q, Bassett R, Valdez BC, Andersson BS, Parmar S, Orlowski RZ, Shah JJ, Thomas SK, Wang M, Champlin RE, Qazilbash M. High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma. Blood (ASH Annual Meeting Abstracts) 122(21), 2013.
167. Shah JJ, Feng L, Thomas SK, Weber DM, Wang M, Hilder B, Alexanian R, Orlowski RZ. Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM). Blood (ASH Annual Meeting Abstracts) 122(21), 2013.
168. Cai Q, Chen Y, Zou D, Badillo M, Zhou S, Zhang L, Lopez ER, Jiang W, Huang H, Lin T, Wang M. Novel Combination Of Lenalidomide-Rituximab Provides An Effective Bridge To Stem Cell Transplantation In Relapsed and/Or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphomas: A Single Center Experience. Blood (ASH Annual Meeting Abstract) 122(21):3056, 2013.
169. Thomas SK, Haygood TM, Qazilbash MH, Melendez AG, Galvis R, Delasalle KB, Feng L, Richards TA, Samaniego F, Wang L, Shah JJ, Orlowski RZ, Weber DM. A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM). Blood (ASH Annual Meeting Abstract) 122(21):4396, 2013.
170. Wang M, Gordon LI, Rule S, Goy A, Hermine O, Rizo A, Zhuang SH, Dreyling MH,. A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL). J Clin Oncol 31, 2013.
171. Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Niesvizky R. Final results from the phase Ib/II study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in patients with relapsed or progressive multiple myeloma. J Clin Oncol 31, 2013.
172. Ou Z, Zhang L, Newberry K, Sun L, Christopher KJ, Rollo A, Tamayo A, Lee J, Ford RJ, Wang M, Pham LV. The bruton's tyrosine kinase inhibitor ibrutinib synergized with the proteasome inhibitor carfilzomib and overcame immunoproteasome-mediated carfilzomib resistance in mantle cell lymphoma. AACR Annual Meeting 2013 73(8 Suppl), 2013.
173. Blonska M, Pan D, Ou Z, Zhang L, Lin X, Wang M. Nuclear accumulation of c-Rel transcription factor is correlated with the proteasome inhibitor resistance in mantle cell lymphoma. AACR Annual Meeting 2013 73(8 Suppl), 2013.
174. Han X, Wang S, Shi Y, Wang M, Zhang L, Fang B, McCauley D, Kauffman M, Shacham S. Novel SINE CRM1 antagonists for non-small cell lung cancer (NSCLC) in vitro and in vivo. AACR Annual Meeting 2013 73(8 Suppl), 2013.
175. Wang M, Rule S, Martin P, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford JA, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry KJ, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy J, Chang BY, Beaupre DM, Kunkel LA, Goy A, Blum KA. Updated interim results of an international, multicenter, phase 2 study of ibrutinib (PCI-32765) in relapsed or refractory (R/R) mantle cell lymphoma (MCL). 12th International Conference on Malignant Lymphoma (ICML), 2013.
176. Wang M, Leo G, Rule S, Goy A, Hermine O, Rizo A, Zhuang SH, Dreyling M. A Phase 3 Study of Ibrutinib in Combination with Bendamustine and Rituximab (BR) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma (MCL). ASCO Annual Meeting, 2013.
177. Wang M, Leo G, Rule S, Goy A, Hermine O, Rizo A, Zhuang SH, Dreyling M. A Phase 3 Study of Ibrutinib in Combination with Bendamustine and Rituximab (BR) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma (MCL). 12th International Conference on Malignant Lymphoma (ICML), 2013.
178. Wang M, Martin P , Blum KA, Kahl BS, Maeda LS, Advani R, Williams ME, Rule S, Rodriguez S, Pang CF, Hedrick E, Goy A. The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. 2012 Highlights of ASH in North America Oral presentation, Atlanta, 2012.
179. Wang M, Popplewell L, Collins RH, Winter JN, Goy A, Robeva A, Pirotta N, Fan J, Klimovsky J, O'Connor OA. Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib. Blood (ASH Annual Meeting Abstracts) 120, 2012.
180. Shah JJ, Thomas SK, Weber DM, Wang M, Alexanian R, Qazilbash MH, Bashir Q, Parmar S, Shah N, Popat UR, Orlowski RZ. Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 120, 2012.
181. Fowler NH, Neelapu SS, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Falane MA, Fayad LE, Orlowski RZ, Wang M, Turturro F, Oki Y, Lacerte LC, Samaniego F. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study. Blood (ASH Annual Meeting Abstracts) 120, 2012.
182. Siegel DS, Wang M, Martin TG, Infante JR, Kaufman JL, Ranjangam K, Huang M, Bilotti E, Vij R. A Phase 2 Study of Prolonged Carfilzomib Therapy in Patients with Multiple Myeloma Previously Enrolled in Carfilzomib Clinical Trials. Blood (ASH Annual Meeting Abstracts) 120, 2012.
183. Oki Y, Westin JR, Fowler N, Neelapu SS, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL. Blood (ASH Annual Meeting Abstracts) 120, 2012.
184. Wang M, Rule SA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, McGreivy J, Clow F, Stevens-Grogan M, Kunkel L, Blum KA. Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up. Blood (ASH Annual Meeting Abstracts) 120, 2012.
185. Parmar S, Howell J, Wang M, Khan MA, Bashir Q, Shah JJ, Shah N, Popat UR, Giralt SA, Orlowski RZ, Qazilbash M. High Dose Therapy Improves Survival in Systemic Light Chain Amyloidosis: 14 Year Follow up. Blood (ASH Annual Meeting Abstracts) 120, 2012.
186. Pham LV, Rollo A, Tamayo AT, Lee J, Zuo Z, Sun L, Zhang L, Ou Z, Fayad LE, Wang M, Ford RJ. Biological Significance of the Immumoproteasome Subunits Mecl-1 and LMP-2 in Diffuse Large B-Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 120, 2012.
187. Shah JJ , Hegde A, Zhou X, Thomas SK, Wang M, Weber DM, Alexanian R, Orlowski RZ, Vadhan-Raj S. Effects of Multiple Myeloma (MM) Therapy and Type of Thromboprophylaxis On the Incidence and Timing of Venous Thromboembolism (VTE) and Factors Predictive of VTE. Blood (ASH Annual Meeting Abstracts) 120, 2012.
188. Kuiatse I, Thomas SK, Weber DM, Stein AM, Wang M, Shah JJ, Treon SP, Ansell SM, Orlowski RZ. Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenström Macroglobulinemia. Blood (ASH Annual Meeting Abstracts) 120, 2012.
189. Dorkhom SJ, Zaman S, Thomas SK, Alexanian R, Shah JJ, Weber DM, Wang M, Anderson ML, Baladandayuthapani V, Lin YH, Fu M, Stellrecht CM, Morales de Partovi C, Gandhi VV, Orlowski RZ. Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 120, 2012.
190. Samaniego F, Wise JF, Tao RH, Zhu H, Ao X, Chen Z, Zhuang W, Braun FK, Mathur R, Romaguera JE, Fayad L, Wang M, McLaughlin P, McDonnell TJ, Patel KP, Neelapu SS, Kwak LW, Berkova Z. Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin. Blood (ASH Annual Meeting Abstracts) 120, 2012.
191. Shah JJ, Orlowski RZ, Thomas SK, Alexanian R, Wang M, Qazilbash MH, Popat UR, Parmar S, Shah N, Bashir Q, Champlin RE, Weber DM. Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma. Blood (ASH Annual Meeting Abstracts) 120, 2012.
192. Shah JJ, Baladandayuthapani V, Weber DM, Thomas SK, Alexanian R, Wang M, Qazilbash MH, Champlin RE, Shah N, Bashir Q, Popat UR, Nieto Y, Ahmed S, Parmar S, Orlowski RZ. Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 122(21), 2012.
193. Wang M, Sun L, Fokt I, Zhang L, Jayakumar A, Priebe W,. Effect of berubicin, the 4'-o-benzylated doxorubicin analog, on growth inhibition and apoptosis in multiple myeloma. J Clin Oncol 30, 2012.
194. Siegel D, Martin T, Wang M, Vij R, Jakubowiak A, Jagannath S, Lonial S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu F, Somlo G, Kunkel L, Wear S, Rajangam K, Chang Y, Orlowski R, Stewart K. Response Rates to Single-Agent Carfilzomib in Patients Double Refractory or Intolerant to Bortezomib and Immunomodulators in Trial PX-171-003-A1. 17th Congress of the European Hematology Association (EHA), 2012.
195. Lee S, Arastu-Kapur S, Kellerman L, Woo T, Wong A, Papadopoulos K, Niesvizky R, Badros A, Vij R, Jagannath S, Siegel D, Wang M, Ahmann G, Kirk C. Potent Inhibition of Select Proteasome Subunits by Carfilzomib in Multiple Myeloma and Solid Tumor Patients is Associated with Patient Response. 17th Congress of the European Hematology Association (EHA), 2012.
196. Lonial S, Baz RC, Wang M, Talpaz M, Liu G, Berg D, Gupta N, Di Bacco A, Hui AM, Richardson PGG. Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM). 2012 ASCO Annual Meeting 30(Suppl), 2012.
197. Patel KK, Orlowski RZ, Weber DM, Wang M, Thomas SK, Shah JJ, Turturro F, Alexanian R, Delasalle K. Prognostic value of serum lactate dehydrogenase in symptomatic multiple myeloma. 2012 ASCO Annual Meeting 30(Suppl), 2012.
198. DiCapua Siegel DS, Martin T, Singhal S, Wang M, Vij R, Jakubowiak AJ, Jagannath S, Lonial S, Kukreti V, Bahlis NJ, Alsina M, Chanan-Khan AAA, Buadi F, Reu FJ, Somlo G, Kunkel LA, Rajangam K, Chang YL, Orlowski RZ, Stewart AK, Myeloma Research Consortium (MMRC). Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1. 2012 ASCO Annual Meeting 30(Suppl), 2012.
199. Wang M, Fowler N, Wagner-Bartak N, Hagemeister F, Neelapu S, Fanale M, Younes A, Zhang L, Sun L, Badillo M, Bejarano M, Champlin R, Kwak L, Feng L, Byrne C, Bell N, Zeldis J, Romaguera J, Fayad L. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in a cohort of patients with DLBCL and grade 3 follicular lymphoma: a completed phase II clinical trial. 16th Congress of the European Hematology Association (EHA), 2012.
200. Shah JJ, Weber DM, Thomas SK, Alexanian R, Wang M, Qazilbash MH, Parmar S, Shah N, Bashir Q, Popat UR, Hilder B, Orlowski RZ. Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstract) 120(21):4082, 2012.
201. Thomas SK, Delasalle KB, Shah JJ, Wang L, Orlowski RZ , Weber DM. Impact of Rituximab On the Treatment of Waldenström's Macroglobulinemia (WM). Blood (ASH Annual Meeting Abstract) 120(21):2734, 2012.
202. Liang R, Wang Z, Chen QX, Bai XQ, Yan GQ, Yang L, Zhang T, Guo Y, Wang L. Analysis of Clinical and Pathological Features of 117 Chinese Cases of Natural Killer/T Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 120(21):5105, 2012.
203. Wang M, Siegel DS, Jakubowiak AJ, Wong AF, Dixon S, Renau TE, Vij R. The Speed of Response to Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: An Exploratory Analysis of Results From 2 Multicenter Phase 2 Clinical Trials. Blood (ASH Annual Meeting Abstract) 118, 2011.
204. Zhang L, Qian J, Ou Z, Sun L, Zhang K, Pham LV, Kirk CJ, Ford RJ, Yi Q, Wang M. Carfilzomib, An Irreversible Proteasome Inhibitor, Induces Long-Term Growth Inhibition of Mantle Cell Lymphoma In Vivo,. Blood (ASH Annual Meeting Abstract) 118, 2011.
205. Zhang K, Pham LV, Zhang L, Tamayo AT, Ou Z, McCauley D, Shacham S, Kauffman M, Ford RJ, Wang M. Novel CRM-1 Inhibitors for Therapy In Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 118, 2011.
206. Ou Z, Pham LV, Zhang L, Tamayo AT, Lee J, Zhang K, Wang J, Phan J, Li C, Sun L, Ford RJ, Wang M. Single-Agent Bruton's Tyrosine Kinase (Btk) Inhibitor and Single-Agent Carfilzomib Induce Cell Apoptosis, Arrest Cell Growth and Downregulate NF-Kb Activity In Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 118, 2011.
207. Vij R, Kaufman JL, Jakubowiak AJ, Wang M, Jagannath S, Kukreti V, McDonagh KT, Alsina M, Bahlis NJ, Belch AR, Reu FJ, Gabrail NY, Matous J, Vesole DH, Orlowski RZ, Wear S, Kunkel L, Wong AF, Lee P, Stewart K. Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM. Blood (ASH Annual Meeting Abstract) 118, 2011.
208. Singhal S, Siegel DS, Martin T, Vij R, Wang M, Jakubowiak AJ, Lonial S, Kukreti V, Zonder JA, Wong AF, McCulloch L, Badros AZ, Niesvizky R, Orlowski RZ, Stewart AK, Kotlovker D, Jagannath S. Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis. Blood (ASH Annual Meeting Abstract) 118, 2011.
209. Romaguera JE, Wang M, Hagemeister F, Weaver P, Hartig K, Fanale M, Fayad LE, Feldman T, Fowler N, Orlowski RZ, Smith J, Ford P, Ekaney M, Kwak LW, Goy A. Phase I/II Study of Bortezomib in Combination with R-HCVAD and R-Methotrexate/Cytarabine (R-MA) in Untreated Mantle Cell Lymphoma (MCL). 11th International Conference on Malignant Lymphoma (ICML), Lugano 22, 2011.
210. Fowler N, Hagemeister F, McLaughlin P, Kwak LW, Romaguera J, Fanale M, Neelapu S, Fayad LE, Orlowski RZ, Wang M, Pro B, Lacerte L, Samaniego F. Lenalidomide Plus Rituximab is a Highly Effective and Well-Tolerated Biologic Therapy in Untreated Indolent B-Cell Non-Hodgkins Lymphoma. 11th International Conference on Malignant Lymphoma (ICML), Lugano 22, 2011.
211. Niesvizky R, Lonial S, Kumar S, Bensinger W, Baz R, Jakubowiak A, Zimmerman T, Berenson J, Wang M, Reeder C, Liu G, Hui AM, Berg D, Gupta N, Richardson P. Evaluation of Twice-Weekly and Weekly Dosing of the Investigational Agent MLN 9708, An Oral Proteasome Inhibitor, In Patients With Relapsed/Refractory Multiple Myleoma: Phase 1 Dose Escalation Studies. 16th Congress of the European Hematology Association (EHA), 2011.
212. Siegel S, Kaufman J, Wang M, Martin T, Jagannath S, Niesvizky R, Reu F, Alsina M, Badros A, Gabrail N, Kukreti V, Singhal S, Le M, Kotlovker D, Bomba D, Hannah A, Vij R. A Summary of Safety and Efficacy Data Achieved With Long-Term Carfilzomib (CFZ) Treatment in Patients With Relapsed and/or Refractory Multiple Myeloma (R/R MM). 16th Congress of the European Hematology Association (EHA), 2011.
213. Jagannath S, Singhal S, Siegel D, Martin T, Wang M, Vij R, Jakubowiak A, Lonial S, Kukreti V, Bahlis N, Chanan-Khan A, Alsina M, Somlo G, Buadi F, Reu F, Song K, Kunkel L, Wong A, Vallone M, Orlowski R, Stewart A. Long-Term Follow-Up in PX-171-003-A1, An Open-Label Single-Arm Phase 2 Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (R/R MM): Analysis by Subgroups of Interst. 16th Congress of the European Hematology Association (EHA), 2011.
214. Cai Z, Wang L, Qian J, Bao H, Yang Y, Zhao Y, He D, Lu P, Li Y, Yang L, Wang M Yi Q. Mantle Cell Lymphoma Cells Express B7 Family Molecules and B7-H1 Expression are Up-Regulated After Interferon-Gamma And LPS Exposure Via Mek-Dependent Pathway in Mantle Cell Lymphoma Cells. 16th Congress of the European Hematology Association (EHA), 2011.
215. Wang M, Bensinger W, Martin T, Alsina M, Siegel DSD, Gabrail NY, Hari P, Singhal S, Vescio RA, Assouline SE, Kunkel LA, Vallone M, Wong A, Niesvizky R. Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM). 2011 ASCO Annual Meeting 29(Suppl), 2011.
216. Jakubowiak AJ, Martin T, Singhal S, Wang M, Vij R, Jagannath S, Lonial S, Kukreti V, Buadi F, Kunkel L, Bray L, Vallone M, Multiple Myeloma Research Consortium (MMRC), Orlowski RZ, Siegel DS. Responses to Single-Agent Carfilzomib (CFZ) are Not Affected by Cytogenetics in Patients (PTS) with Relapsed and Refractory Multiple Myeloma (R/R MM). 11-ICML 22(Suppl 4):iv122, 2011.
217. Romaguera JE, Wang M, Hagemeister F, Weaver P, Hartig K, Fanale M, Fayad LE, Feldman T, Fowler N, Orlowski R, Smith J, Ford P, Ekaney M, Kwak LW, Goy A. Phase I-II Study of Bortezomib in Combination with R-HCVAD and R-Methotrexate/ Cytarabine (R-MA) in Untreated Mantle Cell Lymphoma (MCL). 11-ICML 22(Suppl 4):iv163, 2011.
218. Wang M, Siegel DS, Kaufman JL, Jakubowiak AJ, Stewart AK, Jagannath S, Kukreti, V,McDonagh, KT, Alsina M, Bahlis NJ, Belch A, Reu FJ, Gabrail NY,Matous JV, Rosen P, Lee P, Shustik C, Doner K, Orlowski RZ, Kunkel L, Wong A F, Vij R. Single-agent carfilzomib achieves high response rates in patients with bortezomib-naive relapsed multiple myeloma (MM): updated results from study PX-171-004. 16th Congress of the European Hematology Association (EHA) 2011, 2011.
219. Wang M, Fayad L, Wagner-Bartak N, Hagemeister F, Neelapu S, Finale M, Younes A, Cabanillas F, Zhang L, Champlin R, Kwak L, Feng L, Bell N, Zeldis J, Romaguera J. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in relapsed/refractory mantle cell lymphoma: a completed phase I/II clinical trial. 11th International Conference on Malignant Lymphoma (ICML), Lugano, 2011.
220. Kaufman JL, Vesole DH, Stewart A, Jakubowiak AJ, Jagannath S, Kukreti V, Mcdonagh KT, Alsina M, Reu FJ, Orlowski RZ, Kunkel L, Le MH, Vij R, Wang M. Updated Results for Bortezomib (BTZ)-naïve Patients (Pts) Enrolled in PX-171-004, an Ongoing Open-label, Phase (Ph) 2 Study of Carfilzomib (CFZ), in Relapsed Multiple Myeloma. 11th International Conference on Malignant Lymphoma (ICML), Lugano, 2011.
221. Wang M, Bensinger M, Martin T, Alsina M, Siegel DS, Gabrail NY, Hari P, Singhal S, Vescio RA, Assouline SE, Kunkel LA, Vallone M, Wong A, Niesvizk R. PX-171-006: a Phase (Ph) 2 Multicenter Dose Expansion Study of Carfilzomib (CFZ), Lenalidomide (LEN), and Low-dose Dexamethasone (loDex) in Relapsed and/or Refractory Multiple Myeloma (R/R MM). 2011 ASCO Annual Meeting, 2011.
222. Lu G, Li S, Alseraye F, Muddasani R, Abruzzo L, Wang M, You MJ, Medeiros LJ. Plasma Cell Myeloma with IGHV Deletion: A Subset of Patients with Poor Prognosis. United States and Canadian Academy of Pathology, 2011.
223. Niesvizky R, Bensinger W, Martin T, Alsina M, Siegel DS, Gabrail NY, Hari P, Singhal S, Vescio RA, Assouline SE,Kunkel LA,Vallone M, Wong A, Wang M. An update on the phase 1b/2 dose-escalation study of carfilzomib with lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. 16th Congress of the European Hematology Association (EHA), 2011.
224. Wang M, Garcia K, Zhou Y, You B, Guo Y, Forman A, Chiang J, Orlowski R, Shah J, Alexanian R, Thomas S, Qazilbash M, Badilo M, Chen Y, Delasalle K, Green V, Romaguera J, Cohen L. Electroacupuncture is an effective therapeutic modality for bortezomib- or thalidomide-induced peripheral neuropathy in patients with multiple myeloma: A Pilot Study. 13th International Myeloma Workshop(IMW), 2011.
225. Wang M, Martin P, Blum KA, Kahl BS, Maeda LS, Advani R, Williams ME, Rule S, Rodriguez S, Pang CF, Hedrick E, Goy A. The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. Blood (ASH Annual Meeting Abstract) 118, 2011.
226. Richardson PG, Baz R, Wang M, Jakubowiak AJ, Berg D, Liu G, Gupta N, Bacco AD, Hui AM, Lonial S. Phase I dose-escalation study of investigational agent MLN9708, an oral proteasome inhibitor, in patients (Pts) with relapsed or refractory (Rel/Ref) multiple myeloma (MM). 13th International Myeloma Workshop(IMW), 2011.
227. Ponader S, Balasubramanian S, Pham LV, Chen J, Tamayo AT, Wang M, O'Brien S, Wierda WG, Keating MJ, Ford RJ, Burger JA. Activity of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Mantle Cell Lymphoma (MCL) Identifies Btk As a Novel Therapeutic Target,. Blood (ASH Annual Meeting Abstract) 118, 2011.
228. Wang L, Qian J, Lu Y, Li H, Hong S, Bao H, He D, Liu Z, Zheng Y, He J, Lan Y, Li Y, Neelapu S, Yang J, Wang M, Zhen C, Yi Q. Expression of B7-H1 in Mantle Cell Lymphoma Leads to Inhibition of T Cell Response to Tumor Cells. Blood (ASH Annual Meeting Abstract) 118, 2011.
229. Jakubowiak AJ, Siegel DS, Singhal S, Martin T, Lonial S, Kukreti V, Bahlis N, Khan AC, Alsina M, Somlo G, Buadi FK, Reu RJ, Song KW, Kunkel L, Wear SM, Wong AF, Orlowski RZ, Stewart AK, Jagannath S, Wang M. Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study. Blood (ASH Annual Meeting Abstract) 118, 2011.
230. Wang M, Wang H, Chen Y, Li F, Delasalle K, Alexanian R, Kwak L, Rustveld L, Du X. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: A large population-based study. Haematologica 96(s2):402, 2011. e-Pub 2011.
231. Jakubowiak AJ, Martin T, Singhal S, Wang M, Vij R, Jagannath S, Lonial S, Kukreti V, Buadi F, Kunkel LA, Bray L, Vallone M, Wong AF, Orlowski RZ, Siegel DS, Multiple myeloma research consortium. Effects of cytogenetics on responses and survival in patients with relapsed and refractory multiple myeloma (R/R MM) treated with single-agent carfilzomib (CFZ). 13th International Myeloma Workshop(IMW), 2011.
232. Wang M, Stewart AK, Kaufman JL, Jakubowiak A, Jagannath S, Kukreti V, Mcdonagh K, Alsina M, Bahlis N, Belch A, Reu FJ, Gabrail N, Matous JV, Vesole DH, Orlowski RZ, Kunkel LA, Le MH, Lee P, Rosen PJ, Sebag M, Vij R, Multiple myeloma research consortium (MMRC). Carfilzomib (CFZ) produces a high single-agent response rate with minimal neuropathy even in relapsed multiple myeloma (MM) patients (Pts) with high-risk disease. 13th International Myeloma Workshop(IMW), 2011.
233. Thompson MA, Wei C, Moyer AM, Cunningham JM, Wang M, Fayad L, Feng L, Rodriguez MA, Cabanillas F, Kantarjian HM, Kwak LW, Romaguera JE. Single Nucleotide Polymorphisms (SNPs) in Genes for Glutathione-related Metabolism, Cyclin D1, and DNA Repair as Predictive Biomarkers in Mantle Cell Lymphoma Patients Treated with R-HyperCVAD with Ten Year Clinical Follow-up. Blood (ASH Annual Meeting Abstract) 118, 2011.
234. Khouri IF, Saliba RM, Valverde R, Samuels BI, Korbling M, Alousi AM, Anderlini P, Bashir Q, De Lima M, Hosing C, Kebriaei P, Nieto Y, Popat UR, Qazilbash M, Neelapu S, Fowler NH, Samaniego F, Wang L, Champlin R, Macapinlac HA. Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90yttrium Ibritumomab Tiuxetan (90YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results. Blood (ASH Annual Meeting Abstract) 118(21):662, 2011.
235. Richardson PG, Baz R, Wang L, Jakubowiak AJ, Berg D, Liu G, Gupta N, Di Bacco A, Hui AM, Lonial S. Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study. Blood (ASH Annual Meeting Abstract) 118(21):301, 2011.
236. Shah JJ, Orlowski RZ, Alexanian R, Wang M, Thomas S, Qazilbash MH, Parmar S, Shah N, Bashir Q, Popat U, Weber D. Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma. Blood (ASH Annual Meeting) 116:1948, 2010.
237. Wang M, Sun L, Fokt I, Bao H, Zhang L, Jayakumar A, Priebe W. Berubicin, A Novel Mechanistically Altered Anthracycline Potently Inhibits Cell Growth and Induces Apoptosis in Mantle Cell Lymphoma. 22nd EORTC-NCI-AACR symposium on “Molecular targets and Cancer Therapeutics”, 2010.
238. Priebe W, Wang M, Sun L, Fokt I, Bao H, Zhang L, Jayakumar A. Berubicin, A Topoisomerase II Poison With High CNS Uptake, Inhibits Cell Growth and Induces Apoptosis in Diffuse Large B-Cell Lymphomas. 22nd EORTC-NCI-AACR symposium on “Molecular targets and Cancer Therapeutics”, 2010.
239. Lonial S, Jagannath S, Martin T, Wang M, Singhal S, Trudel S, Le M, Kirk C, Arastu-Kapur S, Vij R, Siegel D. Carfilzomib, A Novel Proteasome Inhibitor, Exhibits Minimal Neurotoxic and Peripheral Neuropahtic Effects in Preclinical and Clinical Studies. 15th Congress of the European Hematology Association (EHA), 2010.
240. Stewart K, Siegel D, Wang M, Kaufman J, Jakubowiak A, Jagannath S, Kukreti V, McDonagh K, Alsina M, Bahlis N, Belch A, Gabrail N, Le M, Bennett M, Vij R. Results of PX-171-004, An Ongoing Open-Label, Phase II Study of Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myleoma (R/R MM) With or Without Prior Bortezomib Exposure. 15th Congress of the European Hematology Association (EHA), 2010.
241. Shah N, Weber DM, Wang M, Thomas S, Shah J, Giralt S, Alexanian R, Orlowski RZ, Qazilbash MH, Avery T. Survival Disparities Between African American and Caucasian Patients With Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma & Leukemia 10(3):E31, 2010.
242. Wang M, Wang ZQ, Sun L, Ma W, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah JJ, Kornblau S, Davis RE. Long-Term Storage in TRIzol has Little Effect on Microarray-Based Gene Expression Profiling in Primary Myeloma or Acute Myeloid Leukemia Cells, 2010.
243. Chen Z, Ayala P, Wang M, Fayad L, Katz RL, Romaguera J, Caraway N, Neelapu SS, Kwak LW, Simmons P, Nami M. Prospective isolation of clongenic mantle cell lymphoma initiating cells. AACR 101st Annual Meeting 70(8 Suppl), 2010.
244. Zhang L, Qian J, Yang J, A Monette, Demo S, Yi Q, Wang M. Carfilzomib, an irreversible proteasome inhibitor, induces caspase-dependent apoptosis and inhibits the growth of mantle cell lymphoma in vitro and in tumor-bearing SCID mice. AACR 100th Annual Meeting 2010, 2010.
245. Martin T, Niesvizky R, Wang M, Orlowski R, Alsina M, Singhal S, Gabrail N, Vallone M, Bui L, Kauffman M, Bensinger W. Phase 2 Multicenter Dose Expansion Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM). 2010 Lymphoma / Myeloma meeting in NYC, 2010.
246. Wang M, Niesvizky R, Orlowski R, Alsina M, Martin T, Singhal S, Gabrail N, Vallone M, Bui L, Kauffman M, Bensinger W. Phase 1b Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM). 2010 Lymphoma / Myeloma meeting in NYC, 2010.
247. Wang M, Bensinger W, Orlowski R, Alsina M, Martin T, Singhal S, Gabrail N, Vallone M, Kauffman M, Niesvizky R,. PX-171-006, a phase Ib dose-escalation study of carfilzomib+lenalidomide+low-dose dexamethsaone in relapsed and/or refractory multiple myeloma. 15th Congress of the European Hematology Association (EHA), 2010.
248. Zheng Y, Yang J, Zhang L, Qian J, Matthews J, Wang M, Kwak L, Yi Q. Novel PI3K Inhibitor Compound A Induces Myeloma Cell Apoptosis and Shows Synergistic Cytotoxicity with Dexamethasone In Multiple Myeloma. Blood (ASH Annual Meeting Abstract) 116(21):4080, 2010.
249. Zhang L, Yang J, Qian J, Neelapu S, Kwak LW, Wang M, Yi Q. Role of Microenvironment In Mantle Cell Lymphoma: IL-6 as An Important Survival Factor for Tumor Cells. Blood (ASH Annual Meeting Abstract) 116(21):3929, 2010.
250. O'Connor OA, Popplewell L, Winter JN, Yuan R, Robeva A, Cauwel H, Chau Q, Wang M. PILLAR-1: Preliminary Results of a Phase II Study of mTOR Inhibitor Everolimus In Patients with Mantle Cell Lymphoma (MCL) Who Are Refractory or Intolerant to Bortezomib. Blood (ASH Annual Meeting Abstract) 116(21):3963, 2010.
251. diCapua Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Jagannath S, Lonial S, Kukreti V, Bahlis NJ, Alsina M, Chanan-Khan AA, Somlo G, Buadi F, Reu FJ, Zonder JA, Song K, Stadtmauer E, Wong AF, Vallone M, Chang YL, Kauffman M, Orlowski RZ, Stewart AK, Singhal SB, The MMRC. Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM). Blood (ASH Annual Meeting Abstract) 116(21):985, 2010.
252. Batty N, Ghonimi E, Feng L, Younes A, Rodriguez A, Wager E, Martinez F, Wang M, McLaughlin P, Fowler N, Hagemeister F. Blood Transfusion and Erythropoiesis Stimulating Agents (ESAs) Use In Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood (ASH Annual Meeting Abstract) 116(21):3357, 2010.
253. Martin T, Singhal SB, Vij R, Wang M, Stewart AK, Jagannath S, Lonial S, Jakubowiak AJ, Kukreti V, Bahlis NJ, Alsina M, Chanan-Khan AA, Somlo G, Buadi F, Reu FJ, Zonder JA, Song K, Stadtmauer EA, Wong AF, Vallone M, Chang YL, Kauffman M, Orlowski RZ, diCapua Siegel DS. Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM). Blood (ASH Annual Meeting Abstract) 116(21):3031, 2010.
254. Wang L, Bao H, Yang Y, Zhao Y, He D, Lu P, Li Y, Yang L, Yi Q, Wang M, Cai Z. Mantle Cell Lymphoma Cells Express B7 Family Molecules and B7-H1 Expression Are up-Regulated After LPS Exposure Via MEK-Dependent and PI3K/Akt-Dependent Pathways In Mantle Cell Lymphoma Cells. Blood (ASH Annual Meeting Abstract) 116(21):3114, 2010.
255. Vij R, Kaufman JL, Jakubowiak AJ, Stewart AK, Jagannath S, Kukreti V, McDonagh KT, Alsina M, Bahlis NJ, Belch A, Reu FJ, Gabrail NY, Matous J, Vesole DH, Orlowski RZ, Le MH, Lee P, Wang M, The MMRC. Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients. Blood (ASH Annual Meeting Abstract) 116(21):1938, 2010.
256. Jakubowiak AJ, Martin T, Singhal SB, Wang M, Vij R, Jagannath S, Lonial S, Kukreti V, Buadi F, Bray L, Vallone M, Kauffman M, Orlowski RZ, diCapua Siegel DS, The MMRC. Responses and Survival Are Not Affected by Cytogenetics In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) Treated with Single-Agent Carfilzomib. Blood (ASH Annual Meeting Abstract) 116(21):1942, 2010.
257. Shah JJ, Zonder JA, Cohen A, Weber D, Thomas S, Wang M, Kaufman JL, Burt SM, Walker D, Freeman B, Rush SA, Ptaszynski A, Orlowski RZ, Lonial S. A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstract) 116(21):1959, 2010.
258. Shah N, Xing D, Lee DA, Cooper LJN, Decker W, Li S, Robinson S, Yang H, Parmar S, Tung S, Wang M, Champlin R, Bollard CM, Shpall EJ. Antigen Presenting Cell-Mediated Ex Vivo Expansion of Human Umbilical Cord Blood Cells Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. Blood (ASH Annual Meeting Abstract) 116(21):2100, 2010.
259. Cai Z, Bao H, Lu P, Wang L, He D, Li H, Yang Y, Zhao Y, Yang L, Li Y, Wang M, Yi Q. Triggering of Toll-Like Receptor-4 In Human Multiple Myeloma Cells Promotes Proliferation and Alters Cell Responses to Immune and Chemotherapy Drug Attack. Blood (ASH Annual Meeting Abstract) 116(21):1905, 2010.
260. Singhal SB, diCapua Siegel DS, Martin T, Vij R, Wang M, Jakubowiak AJ, Lonial S, Kukreti V, Zonder JA, Wong AF, McCulloch L, Kauffman M, Badros AZ, Niesvizky R, Orlowski RZ, Stewart AK, Jagannath S. Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM). Blood (ASH Annual Meeting Abstract) 116(21):1954, 2010.
261. Hunsucker SA, Magarotto V, Matthews JA, Wang M, Baladandayuthapani V, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, and Orlowski RZ. Inhibition of interleukin-6 signaling with CNTO 328 sensitized plasma cell dyscrasias to the effects of melphalan in association with suppression of signaling through protein kinase B/Akt. Blood (ASH Annual Meeting Abstract) 114, 2009.
262. Yang J, Cao Y, Zheng Y, Hong S, Li H, Qian J, Matthews JA, Wang M, Kwak LW, and Yi Q. Constitutive Activation of p38 MAPK in Myeloma Cells Contributes to Myeloma-Induced Osteolytic Bone Lesions. Blood (ASH Annual Meeting Abstracts) 114:740, 2009. e-Pub 2009.
263. Stadtmauer EA, Weber DM, Wang M, Nieszvizky R, Belch A, Prince HM, J. F. Miguel JF, Facon T, Yu Z, Knight RD, Dimopoulos MA. The quality of response to lenalidomide plus dexamethasone is associated with clinical outcomes in patients with relapsed or refractory multiple myeloma. 2009 ASCO Annual Meeting J Clin Oncol 27(15s), 2009.
264. Kuhn DJ, Bjorklund CC, Magarotto V, Matthews JA, Wang M, Baladandayuthapani V, and Orlowski RZ. Bortezomib resistance is mediated by increased signaling through the insulin-like growth factor-1akt axis. 51st ASH Annual Meeting, 2009.
265. Bjorklund CC, Kuhn DJ, Matthews JA, Wang M, Baladandayuthapani V, and Orlowski RZ. Activation of the wnt/β-catenin pathway mediates lenalidomide resistance in multiple myeloma. 51st ASH Annual Meeting 114:111, 2009.
266. Qazilbash M, Saliba R, Pelosini M, Mendoza F, Han E, Wang M, Weber D, Orlowski R, Alousi A, Anderlini P, Hosing C, Kebriaei P, Khouri I Popat U, de Lima M, Champlin R, Giralt S. A randomized Phase II trial of high-dose melphalan, ascorbic acid and arsenic trioxide with or without bortezomib in multiple myeloma. Blood 112(11), 2008.
267. Kazmi S, Mendoza F, Weber D, Wang M, Hosing C, Khouri I, Anderlini P, de Lima M, Kebriaei, Popat U, Champlin R, Giralt S, Qazilbash M. High-dose topotecan, Melphalan and cyclophosphamide (TMC) with autologous stem cell support for multiple myeloma. Blood 112(11), 2008.
268. Wang M, Zhang L, Fayad L, Hagemeister F, Neelapu S, Samaniego F, Pro B, Miller S, Knight R, Zeldis J, Yi Q, Romaguera J. Lenalidomide and rituximab are a promising combination in vitro, in vivo preclinically and in a Phase I/II clinical trial in relapsed/refractory mantle cell lymphoma. Blood 112(11), 2008.
269. Wang M, Giralt S, Delasalle K, Handy B, Alexanian R.. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 12(3):235-239, 2007. PMID: 17558699.
270. Zhang L, Shi Y, Han X, Yang J, Qian J, Kwak L, Romaguera J, Yi Q, Wang M. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Blood (ASH Annual Meeting Abstract) 110(11), 2007.
271. Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar SV, Facon T, Alexanian R, Yu Z, Zeldis J, Olesnyckyj M, Weber D.. Effect of Lenalidomide/Dexamethasone in multiple myeloma despite Thal resistance. Haematologica 92(6):172, (abstr PO-662), 2007.
272. Thomas SK, Delasalle KB, Gavino M, Wang M, Alexanian R, Weber DM.. 2-CDA-cyclophosphamide +/- Rituximab for symptomatic Waldenstrom's Macroglobulinemia. Haematologica 92(6):228, (abstr PO-1227), 2007.
273. Wang M, Delasalle K, Thomas S, Qazilbash M, Giralt S, Weber D, Alexanian R. Early transplant is useful for older patients with multiple myeloma. Haematologica 92(6):189, (abstr PO-819), 2007.
274. Delasalle K, Wang M, Thomas S, Weber D, Alexanian R.. High response rate wtih BCD combination for relapsing multiple myeloma. Haematologica 92(6):158, (abstr PO-616), 2007.
275. Zhou Y, Wang H, Zhang Y, Du X, Kwak L, Romaguera J, Wang M. Trend and geographic variations in the incidence of mantle cell lymphoma in the United States from 1975 to 2003. Proc ASCO 25(185):8091, 2007.
276. Wang M, Fayad L, Hagemeister F, Neelapu S, Bell N, Byrne C, Knight R, Zeldis J, Kwak L, Romaguera J.. A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy. Proc ASCO 25(18S):8030, 2007.
277. Fayad L, Temple S, Pro B, Hagemeister F, Cabanillas F, Samaniego P, McLaughlin P, Wang M, Kwak L, Romaguera J, Rodriguez MA.. R-HCVAD/R-MTX-ARAC is an effective regimen for untreated diffuse large B-cell lymphoma (DLBCL) with aggressive features: M.D. Anderson experience in 40 patients. J Clin Oncol 25(18):8058, 2007.
278. Vadhan-Raj S, Weber D, Wang M, Giralt S, Alexanian R, Thomas S, Zhou X, Patel P, Bueso-Ramos C, Newman R, Aggarwal B.. Curcumin downregulates NF-КB and related genes in patients with multiple myeloma: Results of a phase 1/2 study. Blood 110(11):357a, abstr 1177, 2007.
279. Tam CS, Saliba RM, Ledesma C, Korbling M, Fayad LE, Wang M, Alousi A, Housing C, Kebriaei P, Rondon G, Giralt S, Anderlini P, Popat U, Couriel D, Pro V, Samuels B, Hagemeister FB, Champlin RE, Khouri IF.. Non-myeloablative allogeneic stem cell transplantation (NMT) overcomes the adverse effects of treatment resistance and high Beta-2-Microglobulin in patients with mantle cell lymphoma (MCL): An analysis of 123 transplantations at the M.D. Anderson Cancer Center. Blood 110(11):149a, abstr 484, 2007.
280. Wright J, Weber D, Thomas S, Wang M, Alexanian R, Hawkins V, Vadhan-Raj S.. Characteristics of patients experiencing thromboembolic events during treatment of multiple myeloma: Aspirin may not be adequate as thromboprophylaxis in patients with multiple risk factors. Blood 110(11):557a, abstr 1882, 2007.
281. Thompson MA, Kadia TM, Bekele BN, Wang M, Romaguera J.. Cyclin D1 polymorphisms as predictive and prognostic molecular markers in 90 mantle cell lymphoma patients treated with R-HyperCVAD. Blood 110(11), 2007.
282. Giralt S, Thandi R, Qazilbash M, Mendoza F, Han E, Hosing C, Wang M, Thomas S, Alexanian R, Champlin R, Weber D.. Retrospective comparison of transplant outcomes in patients with multiple myeloma according to induction therapy wtih thalidomide/dexamethasone (TD) with or without bortezomib (VTD). Blood 110(11):288a, abstr 948, 2007.
283. Zhang L, Shi Y, Han X, Yang J, Qian J, Kwak L, Romaguera J, Yi Q, Wang M. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Blood 110(11):4514, 2007.
284. Wang M, Shi Y, Zhang L, Han X, Yang J, Qian J, Hong S, Lin P, Romaguera J, Kwak L, Yi Q.. A SCID-hu in vivo mouse model of human primary mantle cell lymphoma. Blood 110(11):691a, abstr 2337, 2007.
285. Wang M, Zhou Y, Wang H, Yi Q, Zhang Y, Alexanian R, Kwak L, Du X.. Trend and geographic variations in the incidence of Waldenstrom's Macroglobulinemia in the United States over 17 years from 1988 to 2004. Blood 110(11):5174, 2007.
286. Zhou Y, Wang H, Du X, Yi Q, Zhang Y, Romaguera J, Wang M. Trend and geographic variations in the incidence of mantle cell lymphoma in the United States over 30 years from 1975 to 2004. Blood 110(11):4514, 2007.
287. Wang M, Fayad L, Hagemeister F, Neelapu S, Samuels B, Samaniego F, Pro B, Yi Q, Bell N, Byrne C, Weaver P, Hartig K, Knight R, Zeldis J, Kwak L, Romaguera J.. Lenalidomide (Len) in combination with Rituximab demonstrated early evidence of efficacy in a phase I/II study in relapsed/refractory mantle cell lymphoma (MCL). Blood 110(11):755a, abstr 2562, 2007.
288. Qazilbash M, Saliba R, Parikh G, Hosing C. Mendoza F, Quereshi S, Weber D, Wang M, Flosser T, Couriel D, Kebriaei P, Popat U, Alousi A, de Limia M, Champlin R, Giralt S.. Arsenic trioxide with ascorbic acid and high-dose melphalan is safe and effective for autotransplantation for multiple myeloma. Blood 110(11):2661, abstr 942, 2007.
289. Fayad L, Pro B, Hagemeister F, Cabanillas F, Samaniego F, McLaughlin P, Wang M, Neelapu S, Kwak L, Romaguera J, Rodriguez MA.. R-HCVAD/R-MTX-ARAC is an effective regimen for untreated diffuse large B-cell lymphoma (DLBCL) with aggressive features in patients younger than 60 years. Blood 110(11):387a, Abstr 1285, 2007.
290. Parikh G, Saliba R, Lahoti A, Hosing C, Mendoza F, Qureshi S, Weber D, Wang M, Popat U, Alousi A, Champlin R, Giralt S, Qazilbash M.. Autotransplantation in patients with multiple myeloma and concurrent renal failure is safe and feasible and associated with recovery of renal function in >30% of patients. Blood 110(11):5126, 2007.
291. Silva L, Weber D, Wang M, Han E, Mendoza F, de Lima M, Qazilbash M, Champlin R, Giralt S.. 10 years experience with stem cell transplant. Blood 110(11):5112, 2007.
292. Qazilbash M, Saliba R, Parikh G, Hosing C, Mendoza F, Weber D, Wang M, Thomas S, Flosser T, Kebriaei P, Popat U, Alousi A, de Lima M, Champlin R, Giralt S.. A non-myeloablative regimen of fludarabine and melphalan is safe and well tolerated for allogeneic transplantation in multiple myeloma. Blood 110(11):3032, 2007.
293. Alousi A, Hosing C, Saliba R, Valverde R, Maadani F, Korbling M, Okoroji G, Fayad L, Stachowiak A, Erwin W, Anderlini P, de Limia M, Giralt S, Popat U, Kebriaei P, Ueno N, McLaughlin P, Pro B, Wang M, Rodriguez A, Hagemeister F, Macapinlac H, Podoloff D, Champlin R, Khouri I.. Zevalin/BEAM/rituximab vs BEAM/rituximab and autologous stem cell transplantation (ASCT) for relapsed chemosensitive diffuse large B-cell lymphoma (DLBCL): Impact of the IPI and PET status. Blood 110(11):191a, abstr 620, 2007.
294. Qazilbash M, Davis M, Ana A, Roden L, Libunao F, Thall P, Wang X, Couriel D, De Lima M, Hosing C, Kebriaei P, Weber D, Wang M, Jones R, Matthes S, Champlin R, Giralt S.. Arsenic trioxide with ascorbic acid and high-dose melphalan: A new preparative regimen for autologous hematopoietic stem cell transplantation for multiple myeloma. Blood 106(11):338a, (abstr 1159), 2006.
295. Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar SV, Facon T, Yu Z, Zeldis J, Olesnyckyj, Weber DM.. Comparison of lenalidomide in combination with dexamethasone to dexamethasone alone in patients who have received thalidomide in relapsed or refractory multiple myeloma (MM). J Clin Oncol 24(185):7522, 2006.
296. Wang M, Zhang L, Han X, Yang J, Qian J, Wang S, Hong S, Zhang X, Zhou Y, Romaguera J, Yi Q.. Atiprimod inhibits growth of mantle cell lymphoma in vitro and in vivo and induced apoptosis via activation of the mitochondrial pathway. Blood 108(11):712a, (abstr 2514), 2006.
297. Wang M, Delasalle K, Thomas S, Giralt S, Alexanian R.. Complete remission represents the major surrogate marker of long survival in multiple myeloma. Blood 108(11):123a, (abstr 403), 2006.
298. Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar SV, Facon T, Alexanian R, Yu Z, Zeldis J, Olesnyckyj, Weber D.. Lenalidomide in combination with dexamethasone was more effective than dexamethasone in patients who have received prior thalidomide for relapsed or refractory multiple myeloma. Blood 108, 2006.
299. Wang M, Oki Y, Pro B, Romaguera J, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Podoloff D, Samuels B, Loyer E, Zhou Y, Younes A.. Phase II study of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) in patients with relapsed and refractory mantle cell lymphoma (MCL). Blood 108(11):767a, (abstr 2714), 2006.
300. Thomas S, Giralt S, Wang M, Delasalle KB, Gavino M, Rankin K, Alexanian R, Weber DM.. Survival outcomes of patients receiving thalidomide-dexamethasone for previously untreated multiple myeloma. Blood 108(11):1019a (abstr 3569), 2006.
301. Ahmed B, Saliba RM, Ashraf N, Mendoza F, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH.. Deletion of the short arm of chromosome 1 (del 1p) is the strongest predictor of poor outcome in myeloma patients undergoing an autotransplant. Blood 108(11):884a, (abstr 3101), 2006.
302. Qazilbash MH, Saliba RM, Davis MS, Mendoza FL, Hosing C, Couriel DR, de Lima M, Kebriaei P, Weber DM, Wang M, Alousi AM, Matthes SG, Jones RB, Champlin RE, Giralt SA. Arsenic trioxide with ascorbic acid and high-dose melphalan for autologous hematopoietic stem cell transplantation for multiple myeloma. Blood 108(11):881a, (abstr 3090), 2006.
303. Qazilbash M, Saliba R, Hosing C, Mendoza F, Qureshi S, Weber D, Wang M, Flosser T, Couriel D, de Lima M, Kebriaei P, Popat U, Alousi A, Champlin R, Giralt S.. Autologous stem cell transplantation for elderly patients with multiple myeloma. Blood 108(11):450b, (abstr 5422), 2006.
304. Wang M, Alexanian R, Delasalle KB, Weber DM. Confirmation of the Prognostic Value of the International Staging System (ISS) for Multiple Myeloma (MM) Proposed by the International Myeloma Working Group (IMWG) and Southwest Oncology group (SWOG) Staging System with Similar Results Using B2Microglobulin (B2M) Alone. 10th International Myeloma Workshop, Sydney, Australia, 2005.
305. McLaughlin P, Liu N, Poindexter N, Grimm E, Fayad L, Hagemeister F, Nunez R, Romaguera JE, Goy A, Samaniego F, Wang M, Ayala A, Lee B, Reuben J, Kwak L, Rodriguez MA.. Rituximab plus GM-CSF (Leukine) for indolent lymphoma. Ann Oncol 16(S5):68 (abstr 104), 2005.
306. Fayad L, Pro B, Liu Q, Hess M, Hagemeister F, Romaguera J, Samaniego F, Cabanillas F, Rodriguez M, Younes A. Wang M, McLaughlin P.. Time to Treatment Failure (TTF) and FLIPI correlate well with survival and are independent variables in Stage IV indolent follicular lymphoma (IFL). Blood 106(11):274, (abstr 933), 2005.
307. Wang M, Talpaz M, Jagannath S, Alban Chanan-Khan A, Alexanian R, Weber D, Gavino M, Estrov Z, Harris P, Picker D, Schlossman R, Tassone P, Anderson K, Munshi N.. A phase I, multi-center, dose escalation study of atiprimod in patients with refractory or relapsed multiple myeloma (MM). Blood 106(11):36a (abstr 111), 2005.
308. Wang M, Delasalle K, Giralt S, Alexanian A.. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood 106(11):231a (abstr 784), 2005.
309. Donato M, Ana A, Weber D, Wang M, Qazilbash M, Davis M, Roden L, Mendoza F, Champlin R, Giralt S.. Transplant outcomes after topotecan-melphalan-cyclophosphamide (TMC) conditioning for autologous stem cell transplantation for multiple myeloma. Blood 106(11):344a, (abstr 1177), 2005.
310. Romaguera J, Fayad L, Hagemeister F, McLaughlin P, Rodriguez A, Cabanillas F, Younes A, Neelapu S, Goy A, Kantarjian H, Beasley V, Kwak L, Wang M. Relapsed and refractory aggressive mantle cell lymphoma: Preliminary results of salvage therapy with rituximab plus Hyper-CVAD alternating with rituximab plus methotrexate/cytarabine. J Clin Oncol 23:7013-7023, 2005.
311. Romaguera JE, Fayad L, Wang M, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez A, Younes A, Neelapu S, Goy A, Beasley V, Kwak L.. High (95%) response rates in relapsed/refractory mantle cell lymphoma after R-HCVAD alternating wtih R-methotrexate/cytarabine (R-M-A). Blood 106(11):688a, (abstr 2446), 2005.
312. Weber D, Wang M, Delasalle K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine (2-CdA) and cyclophosphamide (Cy) alone or in combination with rituximab (Rit) for previously untreated Waldenstrom’s macroglobulinemia (WM). Blood 104:11 (abstract 1476), 2004.
313. Yao KC, Hentschel SJ, Fourney DR, Wang M, Rhines LD, Burton AW, Mendel E. Percutaneous vertebroplasty and kyphoplasty for painful vertebral compression fractures in patients with multiple myeloma. American Association of Neurological Surgeons (AANS) Annual Meeting, Orlando, FL, 2004.
314. Weber DM, Wang LM, Delasalle KB, Smith T, Alexanian R.. Prognostic features of asymptomatic multiple myeloma. International Multiple Myeloma Conference:71-72, 2004.
315. Goy A, Hart S, Pro B, McLaughlin P, Younes A, Dang N, Fayad L, Romaguera J, Cabanillas F, Hagemeister F, Samaniego F, Wang M, Mesina O, Gilles F, Trehu E, Shenkein D. Report of a phase II study of the proteasome inhibitor bortezomib in patients with relapsed or refractory indolent or aggressive lymphomas. Am J Onc Rev 4(52):5-6, 2004.
316. Giralt S, Aleman A, Lei X, Davis M, Mickler K, Weber D, Wang M, Champlin R. Results of bortezomib (BTZ) therapy for myeloma (MM) patients relapsing after an allogeneic transplant: Preliminary results show efficacy without induction of GVHD. Blood 104:1651, 2004.
317. Alexanian R, Weber D, Wang M, Delasalle K.. Thalidomide-Dexamethasone as primary treatment for multiple myeloma and role of added Bortezomib. International Multiple Myeloma Conference:164-5, 2004.
318. Alexanian R, Wang M, Weber D, Delasalle K,. VTD (Velcade, Thalidomide, Dexamethasone) as primary therapy for newly diagnosed multiple myeloma. Blood 104, 2004.
319. Wang M, Alexanian R, Delasalle K, Mathai V, Weber D. Abnormal MRI of the spine is a major risk factor for early progression of asymptomatic multiple myeloma. Blood 102:11 (abstr 2546), 2003.
320. Wang M, Roifman C, Harris D, Grunberger T, Demin P, Van Q, Rodriguez MA, Talpaz M, Estrov Z.. CR4, a novel protein kinase inhibitor inhibits Stat 3 phosphorylation, suppresses proliferation and induces apoptosis in diffuse large B cell lymphoma cells. Proc ASCO 22:593 (abstr 2383), 2003.
321. Alexanian R, Weber D, Delasalle K, Wang M, Giralt S, Champlin R.. Progressively Reduced Sensitivity of Multiple Myeloma to Serial Intensive Therapies. Blood 102:11 (abst 3654), 2003.
322. Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Thalidomide alone or with dexamethasone for resistant or relapsing multiple Myeloma. Hem Jrnl, IX International Workshop on Multiple Myeloma, Salamanca , Spain 4(S1):S2, 2003.
323. Wang M, Weber D, Alexanian R, Delasalle K, Rankin K, Gavino M.. Thalidomide-dexamethasone vs HyperCVAD as primary therapy for multiple myeloma of high tumor mass. Hem Jrnl 4(S1):352, 2003.

Book Chapters

1. Jain P, Wang M. Blastoid Mantle Cell Lymphoma. In: Hematol Oncol Clin North Am. 5, 941-956, 2020.
2. Avery TP, Shah ND, Fu W, Weber DM, Lu G, Lin P, Qazilbash M, Wang M. Multiple Myeloma and other plasma cell dyscrasias. In: M.D. Anderson Manual of Medical Oncology 2nd Edition. McGraw-Hill Companies, 245-282, 2011.
3. Thomas S, Wang M, Weber D.. Abnormal serum protein electrophoresis. In: Decision Making in Medicine, An Algorithmic Approach. In: Woman's Health. Women's Health, 264-267, 2010.
4. Zhou Y, Alexanian R, Wang M. Targeted Therapy in Multiple Myeloma. In: Targeted Therapy in Cancer. Springer Science+Business Media: Totowa, NJ, 213-236, 2008.
5. Seymour G, Wang M, Weber D.. Multiple myeloma and other plasma-cell dyscrasias. In: M.D. Anderson Manual of Medical Oncology. McGraw-Hill Companies, 175-195, 2006.
6. Jensen, RT, Wang, LH, Lin, JT, Benya, RV, Mroziski, JE, Jr, Coy, DH. Peptide-neuromedin B (NMB) receptor interactions: Comparison with gastrin-releasing peptide (GRP): GRP receptor interactions. In: Growth Factors, Peptides and Receptors. Plenum Publishing Co, 225-37, 1993.

Letters to the Editor

1. Wang M. Commentary on "Bisphosphonates May Potentiate Effects of Thalidomide-Dexamethasone Combination in Advanced Multiple Myeloma". American Journal of Hematology 5: 382-388, 2006.